Connective tissue disorder
MONDO:0003900A disease involving the connective tissue.
Also known as: connective tissue disease, connective tissue disease or disorder, connective tissue diseases, connective tissue disorder, connective tissue disorders, disease of connective tissue, disease or disorder of connective tissue, disease, connective tissue
4076 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsSub-types
Broader categories
Showing the 400 most recently updated of 1728 trials in this tab.
-
New combo pill aims to shrink spleens and ease symptoms in bone marrow cancer
Disease control Recruiting nowThis phase 3 trial tests whether adding pelabresib to the standard drug ruxolitinib works better than ruxolitinib alone for people with myelofibrosis, a type of bone marrow cancer. About 460 adults who have not taken JAK inhibitors before will receive either the combination or a …
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jul 03, 2026 23:00 UTC
-
Could a common arthritis drug tame rare immune disease symptoms?
Disease control Recruiting nowThis early study tests baricitinib, a drug already approved for other immune conditions, in 20 people with Job syndrome who also have lupus-like disease or eczema. Participants take the pill daily for 6 months. The main goal is to see if it is safe and tolerable, while also check…
Phase: PHASE1 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Disease control
Last updated Jul 03, 2026 23:00 UTC
-
Scientists train immune cells to hunt down mutated blood cancers
Disease control Recruiting nowThis early-phase trial tests a personalized treatment for people with blood cancers like leukemia. Doctors take a patient's own T cells, modify them in the lab to recognize unique cancer mutations, and infuse them back after a short course of chemotherapy. The goal is to see if t…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 03, 2026 23:00 UTC
-
New hope for young AML patients: targeted drug combo tested in phase 2 trial
Disease control Recruiting nowThis study tests two different drug combinations for younger adults with a specific type of acute myeloid leukemia (CBF-AML). One group gets standard chemotherapy plus a targeted antibody, while the other gets the same chemotherapy plus a newer targeted pill. The goal is to see w…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 03, 2026 23:00 UTC
-
New radiation approach aims to spare healthy tissue in sinus cancer treatment
Disease control Recruiting nowThis Phase 2 trial tests a new way to give radiation for sinus cancer after endoscopic surgery. Instead of radiating the whole sinus area, doctors will use a 'dose painting' technique that targets only the areas where cancer was found. The goal is to see if this reduces side effe…
Phase: PHASE2 • Sponsor: Centre Francois Baclesse • Aim: Disease control
Last updated Jul 03, 2026 23:00 UTC
-
Fish oil capsules could ease rare muscle disease
Disease control Recruiting nowThis study tests whether omega-3 fatty acid supplements from fish oil, combined with a healthy diet, can reduce disease activity in adults with dermatomyositis, a rare autoimmune disease causing muscle weakness and skin rashes. About 300 participants will take either fish oil cap…
Phase: PHASE2 • Sponsor: National Institute of Environmental Health Sciences (NIEHS) • Aim: Disease control
Last updated Jul 03, 2026 23:00 UTC
-
New pill could ease lupus skin rashes in major trial
Disease control Recruiting nowThis study tests a drug called enpatoran for people with lupus who have active skin rashes or lesions. About 202 participants will take either enpatoran or a placebo twice daily for 24 weeks, alongside their usual treatments. The goal is to see if the drug can significantly impro…
Phase: PHASE3 • Sponsor: EMD Serono Research & Development Institute, Inc. • Aim: Disease control
Last updated Jul 03, 2026 23:00 UTC
-
New Immune-Targeting drug surovatamig enters first human tests for arthritis and lupus
Disease control Recruiting nowThis Phase 1 trial tests surovatamig, a bispecific T-cell engager, in 48 adults with rheumatoid arthritis or systemic lupus erythematosus. The study gives the drug as injections in increasing doses to check safety, side effects, and how the body processes it. It is too early to k…
Phase: PHASE1 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jul 03, 2026 23:00 UTC
-
New combo therapy aims to tame heart sarcoidosis with fewer side effects
Disease control Recruiting nowThis Phase 3 trial compares a low-dose combination of prednisone and methotrexate to standard high-dose prednisone for people with active cardiac sarcoidosis. Researchers hope the combo works just as well but causes fewer side effects and improves quality of life. The study plans…
Phase: PHASE3 • Sponsor: Ottawa Heart Institute Research Corporation • Aim: Disease control
Last updated Jul 03, 2026 23:00 UTC
-
New hope for rare blood cancers: pacritinib trial opens for teens and adults
Disease control Recruiting nowThis study tests an oral drug called pacritinib in people aged 12 and older with myelodysplastic syndromes (MDS) or related blood cancers (MDS/MPN). The goal is to find the best dose and see if it can shrink or control the disease. Participants take capsules twice daily for up to…
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 03, 2026 23:00 UTC
-
New pill aims to calm lupus skin flares in major trial
Disease control Recruiting nowThis study tests an experimental pill called enpatoran for people with lupus who have active skin rashes. About 202 participants will receive either the drug or a placebo for 24 weeks, while continuing their usual treatments. The goal is to see if enpatoran can significantly redu…
Phase: PHASE3 • Sponsor: EMD Serono Research & Development Institute, Inc. • Aim: Disease control
Last updated Jul 03, 2026 23:00 UTC
-
New combo aims for deeper remission in older leukemia patients
Disease control Recruiting nowThis phase II trial tests whether adding gilteritinib to the usual two-drug therapy (azacitidine and venetoclax) can help older or frail adults with a specific type of acute myeloid leukemia (FLT3-mutated) achieve deeper remission. About 147 participants will be randomly assigned…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 03, 2026 23:00 UTC
-
Could a targeted drug boost chemo success in leukemia?
Disease control Recruiting nowThis phase II trial is testing whether adding the drug venetoclax to standard chemotherapy can improve remission rates in younger patients with intermediate-risk acute myeloid leukemia (AML). About 153 participants will receive either standard chemo or a combination with venetocl…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 03, 2026 23:00 UTC
-
New hope for Tough-to-Treat leukemia: multiple drug cocktails tested
Disease control Recruiting nowThis phase II trial tests several experimental drug combinations against the standard treatment for high-risk acute myeloid leukemia (AML) in patients aged 59 or younger. The goal is to see if newer regimens, including venetoclax and liposome formulations, can better shrink cance…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 03, 2026 23:00 UTC
-
Second-Time ACL repair: new technique shows promise for knee stability
Disease control Recruiting nowThis study looks at how well a particular revision ACL surgery works over the long term. The technique uses a donor Achilles tendon and an extra stitch on the outside of the knee. Researchers will check knee function, stability, and arthritis development in 59 people who had this…
Sponsor: Stefano Zaffagnini • Aim: Disease control
Last updated Jul 03, 2026 23:00 UTC
-
New combo aims to stop leukemia from coming back
Disease control Recruiting nowThis phase 2 trial tests whether giving olutasidenib with azacitidine, followed by olutasidenib alone as maintenance, can keep acute myeloid leukemia (AML) with an IDH1 mutation from returning. The study enrolls 28 adults who have already achieved remission after initial treatmen…
Phase: PHASE2 • Sponsor: University of California, Davis • Aim: Disease control
Last updated Jul 03, 2026 23:00 UTC
-
New pill plus chemo shows promise for kids with tough cancers
Disease control Recruiting nowThis study tests an experimental pill called silmitasertib combined with standard chemotherapy in children and young adults (under 30) whose solid tumors (like neuroblastoma, Ewing sarcoma, or osteosarcoma) have come back or not responded to treatment. The goal is to find a safe …
Phase: PHASE1, PHASE2 • Sponsor: Milton S. Hershey Medical Center • Aim: Disease control
Last updated Jul 03, 2026 23:00 UTC
-
Immune cell injection takes on Hard-to-Treat leukemia
Disease control Recruiting nowThis early-stage trial tests an experimental cell therapy called IBR733 for adults with acute myeloid leukemia (AML) that has returned or not responded to standard treatment. The therapy involves giving immune cells by vein in repeated cycles. The main goals are to check safety, …
Phase: PHASE1 • Sponsor: Imbioray (Hangzhou) Biomedicine Co., Ltd. • Aim: Disease control
Last updated Jul 03, 2026 23:00 UTC
-
New lupus drug E6742 enters Mid-Stage trial
Disease control Recruiting nowThis phase 2 trial tests whether the experimental drug E6742 can reduce lupus disease activity better than a placebo. About 256 adults with lupus will take either E6742 or a placebo pill for 24 weeks. The main goal is to see if more people on E6742 achieve a meaningful reduction …
Phase: PHASE2 • Sponsor: Eisai Co., Ltd. • Aim: Disease control
Last updated Jul 03, 2026 23:00 UTC
-
Experimental drug cocktail aims to tame deadly transplant complication
Disease control Recruiting nowThis early-phase trial is testing whether adding the drug emapalumab to standard medications can safely prevent graft-versus-host disease (GVHD) in 15 adults with leukemia or myelodysplastic syndrome receiving a reduced-intensity stem cell transplant. Emapalumab blocks a protein …
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
New study tests ilaris to tame rare inflammatory disease
Disease control Recruiting nowThis study looks at how well and how safely the drug Ilaris (canakinumab) works for people with Schnitzler's syndrome, a rare condition that causes hives, fever, joint pain, and fatigue. About 5 participants will receive the drug and be monitored for up to 48 weeks. The goal is t…
Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
New shoulder implant under real-world scrutiny: will it hold up?
Disease control Recruiting nowThis study follows adults who have received a Tipmed shoulder replacement to see how well the implant works and if any problems arise over the first year. Participants have conditions like severe arthritis, rotator cuff damage, or a broken shoulder bone. Researchers track shoulde…
Sponsor: TIPMED Medical Device Manufacturing Ltd. Co. • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
New Dual-Target CAR T-Cell therapy aims to beat relapsed childhood cancers
Disease control Recruiting nowThis study tests a new type of CAR T-cell therapy that targets two proteins, CD19 and CD22, on cancer cells. It is for children and young adults aged 3 to 39 with B-cell cancers like leukemia or lymphoma that have not been cured by standard treatments. Participants receive their …
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
New hope for rare sarcomas: chemo plus immunotherapy combo enters phase III trial
Disease control Recruiting nowThis Phase III trial tests whether adding the immunotherapy drug pembrolizumab to standard chemotherapy (doxorubicin) helps people with advanced dedifferentiated liposarcoma or undifferentiated pleomorphic sarcoma live longer without their cancer worsening. About 365 adults whose…
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
Blood disorder drug luspatercept gets Long-Term safety review
Disease control Recruiting nowThis study follows about 665 people with myelodysplastic syndromes, beta-thalassemia, or myelofibrosis who have already taken luspatercept in earlier trials. Researchers want to see how safe the drug is over many years by tracking side effects, disease progression, and survival. …
Phase: PHASE3 • Sponsor: Celgene • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
Lupus trial tests NAD+ booster to tame immune system
Disease control Recruiting nowThis study tests whether a supplement called nicotinamide riboside (NR) can reduce inflammation and improve immune cell function in women with mild-to-moderate lupus. About 78 participants will receive either NR or a placebo for 12 weeks. Researchers will measure changes in immun…
Phase: PHASE1, PHASE2 • Sponsor: National Heart, Lung, and Blood Institute (NHLBI) • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
New hope for tough leukemia: first human trial of KK2845 begins
Disease control Recruiting nowThis early-stage study tests a new drug called KK2845 for adults whose acute myeloid leukemia (AML) has returned or not improved after standard treatments. The goal is to find a safe dose and see how well the body tolerates it. About 72 participants will take part in two phases: …
Phase: PHASE1 • Sponsor: Kyowa Kirin Co., Ltd. • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
New drug aims to limit heart damage after major attack
Disease control Recruiting nowThis study tests a medicine called Xolatryp in adults who have had a severe heart attack (STEMI) and are getting a procedure to open blocked arteries. Participants receive either a single 6-hour infusion of Xolatryp or a placebo, and their heart health is monitored for 30 days. T…
Phase: PHASE2 • Sponsor: Nyrada Pty Ltd • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
New drug ABBV-519 enters first human tests for lupus and arthritis
Disease control Recruiting nowThis early-stage study tests a single dose of ABBV-519 in 30 adults with moderate lupus or rheumatoid arthritis. Researchers will check how the drug moves through the body, how it affects immune cells, and whether it is safe. Participants will be followed for about a year to moni…
Phase: PHASE1 • Sponsor: AbbVie • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
Blood test could help rheumatoid arthritis patients safely reduce medication
Disease control Recruiting nowThis study tests a new tool called OPTIBIO that uses blood markers and patient data to help doctors decide if it's safe to reduce biological therapy in rheumatoid arthritis patients who are in remission. About 184 adults with RA in stable remission will be randomly assigned to ha…
Phase: NA • Sponsor: Francisco J. Blanco • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
New drug cocktail aims to beat back stubborn leukemia
Disease control Recruiting nowThis study tests a combination of four drugs, called CLAG-GO, in adults whose acute myeloid leukemia (AML) has not responded to standard treatment or has come back after remission. Participants receive the drugs during a hospital stay, and if the cancer goes into remission, they …
Phase: PHASE2 • Sponsor: University of Maryland, Baltimore • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
New transplant cocktail aims to tame blood cancer without severe side effects
Disease control Recruiting nowThis early-stage trial is testing a new combination of chemotherapy drugs (thiotepa, busulfan, and fludarabine) followed by a stem cell transplant for people with certain blood cancers like leukemia and myelodysplastic syndrome. The goal is to see if this approach can reduce the …
Phase: PHASE1 • Sponsor: Sawa Ito, MD • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
Engineered donor cells aim to make stem cell transplants safer for blood cancer patients
Disease control Recruiting nowThis study tests a new way to prepare donor stem cells (called Orca-Q) for people with blood cancers like leukemia or MDS who need a transplant. The goal is to see if this engineered graft is safe and helps the body accept the new cells with fewer complications. About 300 partici…
Phase: PHASE1 • Sponsor: Orca Biosystems, Inc. • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
New hope for kids with joint pain: risankizumab trial launches
Disease control Recruiting nowThis study tests a drug called risankizumab in children with juvenile psoriatic arthritis, a condition causing joint pain and swelling. About 40 kids will receive either risankizumab or the standard drug adalimumab for 24 weeks, with responders continuing for up to 2 years. The g…
Phase: PHASE3 • Sponsor: AbbVie • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
New drug could reduce Blood-Letting for polycythemia vera patients
Disease control Recruiting nowThis phase 3 trial tests whether adding the drug sapablursen to standard treatment helps people with polycythemia vera, a blood disorder causing too many red blood cells. About 250 participants who currently need regular blood removal (phlebotomy) will receive either sapablursen …
Phase: PHASE3 • Sponsor: Ono Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
New lupus drug tracked in global real-world study
Disease control Recruiting nowThis study follows 200 adults with lupus who are starting anifrolumab for the first time, to see how well it works in everyday clinics. Researchers will measure disease activity, skin symptoms, fatigue, and quality of life over time. The goal is to provide real-world evidence to …
Sponsor: AstraZeneca • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
Experimental drug TURALIO takes on tough childhood cancers in early trial
Disease control Recruiting nowThis early-phase study tests the drug TURALIO (pexidartinib) in people aged 3 to 35 whose cancer has not responded to standard treatments. The goal is to find a safe dose and see if it can shrink tumors or control leukemia. Participants take a daily capsule for up to 2 years, wit…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
Could a targeted pill boost chemo for tough blood cancer?
Disease control Recruiting nowThis Phase 3 trial tests whether adding the drug venetoclax to standard chemotherapy helps adults with newly diagnosed acute myeloid leukemia (AML) or a related high-risk condition. About 650 participants aged 18 to 75 will receive either venetoclax or a placebo alongside chemo. …
Phase: PHASE3 • Sponsor: University of Ulm • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
New stem cell approach aims to fight tough childhood cancers
Disease control Recruiting nowThis study tests a special stem cell transplant for children, teens, and young adults (ages 6 months to 25 years) with solid tumors that have come back or not responded to treatment. The transplant uses cells from a donor, with certain immune cells removed to reduce side effects,…
Phase: PHASE1, PHASE2 • Sponsor: University of Florida • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
New mRNA injection aims to tame autoimmune diseases
Disease control Recruiting nowThis early-phase trial is testing a new drug called MTS109, made with mRNA technology, for people with moderate to severe autoimmune diseases like lupus and scleroderma. Fifteen participants will receive several injections over a month to see if it is safe and tolerable. The goal…
Phase: EARLY_PHASE1 • Sponsor: Shanghai Changzheng Hospital • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
Experimental triple therapy aims to tame leukemia without intensive chemo
Disease control Recruiting nowThis phase I trial tests whether adding the experimental drug iadademstat to two standard leukemia medications (azacitidine and venetoclax) is safe and tolerable for adults with newly diagnosed acute myeloid leukemia (AML) who cannot undergo intensive chemotherapy. Iadademstat bl…
Phase: PHASE1 • Sponsor: OHSU Knight Cancer Institute • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
Lupus drug trial aims for remission without daily pills
Disease control Recruiting nowThis study tests a drug called mosunetuzumab in 30 people with lupus, a disease where the immune system attacks the body. The goal is to see if the drug can put lupus into remission so that participants can stop most lupus medications for at least 6 months. However, some people m…
Phase: PHASE2 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
Promising new pill for kids with chronic leukemia enters testing
Disease control Recruiting nowThis study is testing an oral medication called asciminib in children aged 1 to 18 with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML-CP) who have already tried other treatments. The goal is to find the right dose that works as well as it does in adults and t…
Phase: PHASE1, PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
Engineered immune cells take on tough autoimmune diseases
Disease control Recruiting nowThis early-stage trial tests an experimental treatment called QEL-005 for people with two serious autoimmune conditions: diffuse cutaneous systemic sclerosis and difficult-to-treat rheumatoid arthritis. QEL-005 is made from a patient's own white blood cells, which are genetically…
Phase: PHASE1, PHASE2 • Sponsor: Quell Therapeutics Limited • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
New RA drug enters first human safety trial
Disease control Recruiting nowThis study tests a new medicine called SBT777101 in 24 people with moderate-to-severe rheumatoid arthritis (RA). It is the first time this drug is given to humans, so the main goal is to check safety and side effects. Participants receive a single dose, and the dose is increased …
Phase: PHASE1 • Sponsor: Sonoma Biotherapeutics, Inc. • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
New lupus drug aims to help patients stop steroids
Disease control Recruiting nowThis study tests a medicine called anifrolumab for people with lupus who have not taken strong immune-suppressing drugs before. The goal is to see if the drug can help patients reach remission and reduce or stop their steroid use. About 245 adults will receive weekly injections f…
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New hope for tough arthritis cases: experimental drug enters Mid-Stage trial
Disease control Recruiting nowThis study tests an experimental drug called Afimkibart (RO7790121) in 160 people with moderate to severe rheumatoid arthritis who did not get better with or could not tolerate standard treatments like TNF or JAK inhibitors. Participants will receive either the drug or a placebo …
Phase: PHASE2 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New drug aims to tame lupus flares
Disease control Recruiting nowThis study tests an experimental drug called IMC-002 (also known as IMM0306) in people with active systemic lupus erythematosus (SLE), a chronic autoimmune disease. The trial compares the drug against a placebo, both given alongside standard care, to see if it can reduce disease …
Phase: PHASE1, PHASE2 • Sponsor: ImmuneCare Biopharmaceuticals (Shanghai) Co., Ltd. • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New drug combo aims to tame immune attack after stem cell transplants
Disease control Recruiting nowThis phase 2 trial tests whether adding vedolizumab to standard drugs (cyclophosphamide and tacrolimus) can prevent graft-versus-host disease (GVHD) in people receiving stem cell transplants for blood cancers like leukemia and myelodysplastic syndrome. GVHD occurs when donor immu…
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
Morning or evening? timing your RA pill could boost relief
Disease control Recruiting nowThis study tests whether taking a once-daily JAK inhibitor for rheumatoid arthritis in the evening works better than taking it in the morning. About 90 adults with RA who qualify for this medication will be randomly assigned to morning or evening dosing. Researchers will compare …
Sponsor: Centre Hospitalier Princesse Grace • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
Experimental CAR t therapy takes on tough leukemia
Disease control Recruiting nowThis early-phase trial tests a new treatment called CD64 CAR T cells for adults with acute myeloid leukemia (AML) that has come back or not responded to standard therapy. The treatment uses a patient's own immune cells, modified in a lab to target and attack leukemia cells. The m…
Phase: PHASE1 • Sponsor: University of Colorado, Denver • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New hope for AML patients: targeted drug ziftomenib enters final testing phase
Disease control Recruiting nowThis large Phase 3 trial is testing whether adding the experimental drug ziftomenib to standard chemotherapy helps people with untreated acute myeloid leukemia (AML) who have specific genetic mutations. About 1,300 participants will be randomly assigned to receive either ziftomen…
Phase: PHASE3 • Sponsor: Kura Oncology, Inc. • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New pill could ease psoriatic arthritis without biologics
Disease control Recruiting nowThis Phase 3 study tests whether the oral drug zasocitinib (TAK-279) can improve symptoms of active psoriatic arthritis in people who have never used biologic treatments. About 1,088 adults will receive either zasocitinib, an active comparator, or a placebo for up to 60 weeks. Th…
Phase: PHASE3 • Sponsor: Takeda • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
Engineered immune cells take on lupus in early trial
Disease control Recruiting nowThis early-stage study tests a new treatment called CHT101 for people with severe lupus that hasn't improved with standard treatments. CHT101 uses specially engineered immune cells (CAR-T cells) to target and destroy certain immune cells that drive lupus. The study will enroll 15…
Phase: EARLY_PHASE1 • Sponsor: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
Experimental leukemia drug made available for patients who have no other options
Disease control AVAILABLEThis program provides expanded access to the experimental drug ziftomenib for adults with acute myeloid leukemia (AML) or acute lymphoblastic leukemia (ALL) that has specific genetic changes (KMT2A rearrangements or NPM1 mutations). It is for patients who have exhausted standard …
Sponsor: Kura Oncology, Inc. • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New drug tulisokibart aims to ease psoriatic arthritis pain
Disease control Recruiting nowThis study tests a new medicine called tulisokibart for people with active psoriatic arthritis, a condition causing joint pain and skin plaques. Researchers will compare different doses of the drug to a placebo in 140 adults to see if it improves symptoms like joint tenderness an…
Phase: PHASE2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New CML drug combo strategy aims for deeper remission without lifelong side effects
Disease control Recruiting nowThis study tests a new drug, asciminib, as the first treatment for adults newly diagnosed with chronic myeloid leukemia (CML). If the drug alone does not achieve a deep response within 2 to 3 years, a low dose of another targeted therapy is added. The goal is to see if this appro…
Phase: PHASE2 • Sponsor: University of Alabama at Birmingham • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
Engineered immune cells take aim at autoimmune diseases
Disease control Recruiting nowThis early-stage trial tests a new treatment called AZD0120 for adults with three autoimmune diseases: systemic sclerosis, idiopathic inflammatory myopathies, or difficult-to-treat rheumatoid arthritis. AZD0120 is made from a patient's own immune cells, which are modified in a la…
Phase: PHASE1 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New pill could ease psoriatic arthritis pain in major trial
Disease control Recruiting nowThis Phase 3 trial tests whether the experimental drug zasocitinib (TAK-279) can reduce joint swelling and pain in people with active psoriatic arthritis. About 600 adults will receive either the drug or a placebo for up to 60 weeks. The main goal is to see if more people on the …
Phase: PHASE3 • Sponsor: Takeda • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New drug aims to calm immune attacks on kidneys
Disease control Recruiting nowThis Phase 2 study tests atacicept, a drug that may reduce immune system attacks on the kidneys. About 250 adults with various autoimmune kidney diseases (like IgA nephropathy or membranous nephropathy) will receive weekly injections. Researchers will check safety and measure cha…
Phase: PHASE2 • Sponsor: Vera Therapeutics, Inc. • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New drug afimkibart tested for Long-Term arthritis control
Disease control Recruiting nowThis study is testing the long-term safety and effectiveness of a drug called afimkibart in people with moderate to severe rheumatoid arthritis. Participants have already taken afimkibart in a previous study and will continue taking it. The goal is to see if the drug remains safe…
Phase: PHASE2 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New drug combo aims to improve leukemia treatment before transplant
Disease control Recruiting nowThis study is for adults with a certain type of acute myeloid leukemia (AML) who are in remission and planning a stem cell transplant. It compares a combination of two drugs, venetoclax and azacitidine, against standard high-dose chemotherapy as a 'consolidation' step before the …
Phase: PHASE2 • Sponsor: The First Affiliated Hospital of Soochow University • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New hope for kids with arthritis: experimental drug enters final testing phase
Disease control Recruiting nowThis study tests a drug called deucravacitinib in children aged 5 to 17 with active juvenile psoriatic arthritis, a condition causing joint pain and swelling. The trial aims to see if the drug can control the disease and prevent flare-ups. About 60 participants will receive eithe…
Phase: PHASE3 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
Experimental drug combo aims to shrink Hard-to-Treat sarcomas
Disease control Recruiting nowThis early-stage trial tests a combination of two drugs—peposertib and a low-dose form of the chemotherapy doxorubicin—in people with advanced sarcomas that have spread or can't be removed by surgery. The goal is to find the safest dose and see if the combo can shrink tumors or s…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New hope for AML patients who fail venetoclax?
Disease control Recruiting nowThis pilot study tests the drug olutasidenib, with or without azacitidine, in 25 adults with a specific type of acute myeloid leukemia (IDH1-mutated) that has returned or not responded after venetoclax treatment. The goal is to see if the cancer can be brought into remission. Par…
Phase: PHASE2 • Sponsor: Timothy Pardee • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New drug aims to stop leukemia from coming back after transplant
Disease control Recruiting nowThis early-phase trial tests a drug called DR-18 in 40 adults with acute myeloid leukemia or myelodysplastic syndrome whose cancer returned or persisted after a stem cell transplant. DR-18 is a modified immune protein designed to boost the body's natural defenses against cancer c…
Phase: PHASE1 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New pill could tame rare blood disorder without chemotherapy
Disease control Recruiting nowThis phase 3 trial compares bomedemstat, an experimental oral drug, to hydroxyurea (standard therapy) in 300 people with essential thrombocythemia who have not yet received cytoreductive treatment. The goal is to see if bomedemstat better controls platelet counts and prevents com…
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New combo aims to beat High-Risk leukemia and MDS
Disease control Recruiting nowThis phase II trial tests whether adding targeted total marrow irradiation to standard chemotherapy before a stem cell transplant can improve outcomes for people with high-risk acute myeloid leukemia, chronic myeloid leukemia, or myelodysplastic syndromes. The study will enroll 3…
Phase: PHASE2 • Sponsor: University of Illinois at Chicago • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New lupus drug shows promise in major trial
Disease control Recruiting nowThis study tests an experimental drug called dapirolizumab pegol for people with moderate to severe lupus. About 450 participants will receive either the drug or a placebo, added to their usual treatments. The goal is to see if the drug can improve lupus symptoms over 48 weeks.
Phase: PHASE3 • Sponsor: UCB Biopharma SRL • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
Engineered immune cells take aim at stubborn blood cancers
Disease control Recruiting nowThis study tests a new type of immunotherapy called CAR-T cells that are designed to recognize and attack cancer cells carrying a protein called CD7. It includes people with several blood cancers, such as T-cell acute lymphoblastic leukemia and acute myeloid leukemia. The goal is…
Phase: PHASE1, PHASE2 • Sponsor: Shenzhen Geno-Immune Medical Institute • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
Could a targeted drug boost chemo for osteosarcoma?
Disease control Recruiting nowThis trial is testing whether adding the targeted drug cabozantinib to standard chemotherapy (methotrexate, doxorubicin, and cisplatin) helps people with newly diagnosed osteosarcoma, a type of bone cancer. The study includes over 1,100 participants and aims to see if the combina…
Phase: PHASE2, PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
New drug HC-7366 tested for tough leukemia
Disease control Recruiting nowThis early-phase trial is testing a new drug called HC-7366 in 18 adults with acute myeloid leukemia (AML) that has come back or not responded to other treatments. The main goal is to find a safe dose and check for side effects. Researchers hope this drug may offer a new option f…
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
Engineered immune cells aim to tame lupus without daily pills
Disease control Recruiting nowThis phase 2 trial tests a one-time treatment called CC-97540, made from a patient's own immune cells engineered to target and calm the overactive immune system in lupus. The study enrolls 89 adults with active lupus (including kidney inflammation) who have not responded well to …
Phase: PHASE2 • Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
Can a simple blood draw reduce transfusions in bone cancer surgery?
Disease control Recruiting nowThis study tests a technique called acute normovolemic hemodilution (ANH) in 150 adults undergoing bone tumor surgery. Before surgery, some blood is removed and replaced with fluid, so that if bleeding occurs, the patient loses less red blood cells. The goal is to see if this red…
Phase: NA • Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
New study tracks best approaches for returning abdominal sarcoma
Disease control Recruiting nowThis study follows 100 adults whose retroperitoneal liposarcoma has returned after initial surgery. Researchers will compare outcomes of surgery alone versus radiation and/or chemotherapy before surgery. The goal is to improve treatment decisions and validate a prediction tool fo…
Sponsor: Australia and New Zealand Sarcoma Association • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
Engineered immune cells take aim at Hard-to-Treat leukemia
Disease control Recruiting nowThis early-stage trial tests a new treatment called CD4CAR T cells for people with chronic myelomonocytic leukemia (CMML) that has come back or not responded to standard care. The treatment uses a patient's own immune cells, modified in a lab to recognize and attack cancer cells.…
Phase: PHASE1 • Sponsor: Huda Salman • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
New drug combo aims to beat tough leukemia
Disease control Recruiting nowThis phase 3 trial tests whether adding the drug revumenib to standard intensive chemotherapy helps people with newly diagnosed acute myeloid leukemia (AML) that has a specific genetic change (NPM1 mutation). About 468 participants will receive either revumenib or a placebo along…
Phase: PHASE3 • Sponsor: Syndax Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
New lupus pill enters Mid-Stage trial – hope for better control?
Disease control Recruiting nowThis study tests an experimental oral drug called BI 3000202 in 405 adults with moderate to severe systemic lupus erythematosus (SLE). Participants are randomly assigned to one of four doses of the drug or a placebo, taken daily for a year alongside their usual lupus treatments. …
Phase: PHASE2 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
Which comes first? new study aims to optimize AML treatment sequence
Disease control Recruiting nowThis phase II trial is for older adults with a specific type of acute myeloid leukemia (AML) that has IDH gene mutations. Researchers want to find out whether starting treatment with an IDH-targeted drug (ivosidenib or enasidenib) followed by standard therapy (azacitidine plus ve…
Phase: PHASE2 • Sponsor: Alice Mims • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
New drug combo aims to make stem cell transplants safer for blood cancer patients
Disease control Recruiting nowThis Phase 2 trial is testing a stem cell transplant from a donor for people with various blood cancers and bone marrow disorders. The transplant uses strong chemotherapy or radiation to wipe out the diseased marrow, then replaces it with healthy donor cells. A new combination of…
Phase: PHASE2 • Sponsor: Masonic Cancer Center, University of Minnesota • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
Engineered immune cells take on tough leukemia
Disease control Recruiting nowThis early-phase trial tests a new type of cell therapy for people with relapsed or refractory acute myeloid leukemia (AML). The treatment uses a patient's own immune cells, engineered to recognize six different targets on leukemia cells. The study aims to see if this approach is…
Phase: PHASE1, PHASE2 • Sponsor: Shenzhen Geno-Immune Medical Institute • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New drug combo aims to tame painful muscle condition and cut steroid dependence
Disease control Recruiting nowThis study tests whether adding sarilumab (a drug that calms inflammation) to a slow steroid taper can help people with early polymyalgia rheumatica achieve lasting remission. About 300 adults aged 50 and older will receive either sarilumab or a placebo, along with a 52-week pred…
Phase: PHASE4 • Sponsor: Sanofi • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New drug AZD5492 tested for autoimmune diseases in first human study
Disease control Recruiting nowThis Phase 1 trial tests the safety and tolerability of a new drug called AZD5492 in 72 adults with lupus, myositis, or rheumatoid arthritis. Participants receive one or two doses under the skin and are monitored for side effects and how the drug moves through the body. The study…
Phase: PHASE1 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New universal CAR t therapy targets tough blood cancers
Disease control Recruiting nowThis early-stage trial tests a new type of immune cell therapy (called universal CAR T cells) for people with certain blood cancers, including T-cell leukemia and lymphoma. The therapy targets a protein called CD7 found on cancer cells. The study will check if the treatment is sa…
Phase: PHASE1 • Sponsor: Shenzhen Geno-Immune Medical Institute • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New drug AZD1163 aims to ease rheumatoid arthritis pain
Disease control Recruiting nowThis study tests an experimental drug called AZD1163 in 320 people with moderate-to-severe rheumatoid arthritis who haven't gotten enough relief from standard treatments. Participants receive either AZD1163 or a placebo as an injection, along with their usual care. The main goal …
Phase: PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New drug combo aims to outsmart resistant leukemia
Disease control Recruiting nowThis early-phase trial is testing whether combining two oral drugs, eltanexor and venetoclax, is safe and effective for people with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) that has returned or not responded to prior treatment. The study will enroll 60 adult…
Phase: PHASE1 • Sponsor: Vanderbilt-Ingram Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Lupus drug may shield heart and arteries
Disease control Recruiting nowThis study tests whether anifrolumab, a drug that blocks certain immune signals, can improve blood vessel function and reduce inflammation in people with lupus. About 45 adults with lupus will receive either the drug or a placebo over 8 months. Researchers will measure changes in…
Phase: PHASE2 • Sponsor: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New hope for kids with tough leukemia: chemo combo trial launches
Disease control Recruiting nowThis early-phase trial is testing a combination of two drugs—Hyper-CVAD chemotherapy and venetoclax—in 22 children and young adults whose leukemia has returned or not responded to treatment. The main goal is to find a safe dose and monitor side effects. If the combination proves …
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New Pill-and-Shot combo aims to tame thick blood
Disease control Recruiting nowThis study tests whether a new pill (gecacitinib) plus a weekly injection (pegylated interferon) can help people with polycythemia vera, a condition where the body makes too many red blood cells. The goal is to bring blood counts back to normal and ease symptoms. Thirty adults wi…
Phase: NA • Sponsor: Duan Minghui • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New pill could ease arthritis in kids – major trial underway
Disease control Recruiting nowThis study tests whether baricitinib, a daily pill, is safe and works for children aged 1 to under 18 with systemic juvenile idiopathic arthritis (sJIA), a chronic inflammatory disease. About 58 children will receive either baricitinib or a standard injected drug (tocilizumab) to…
Phase: PHASE3 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New cell therapy aims to make mismatched donor transplants safer for blood cancer patients
Disease control Recruiting nowThis early-phase trial tests a cell therapy called Orca-T combined with standard drugs to prevent graft-versus-host disease (GVHD) in 24 adults with advanced blood cancers (like leukemia or MDS) receiving stem cell transplants from partially matched donors. The main goal is to se…
Phase: PHASE1 • Sponsor: Stanford University • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Engineered immune cells aim to clear leukemia before transplant
Disease control Recruiting nowThis early-phase trial is testing a new type of CAR T-cell therapy, called CD4CAR, in people with acute myeloid leukemia (AML) that has come back or not responded to standard treatment. The therapy targets a protein called CD4 on leukemia cells. The goal is to safely eliminate as…
Phase: PHASE1 • Sponsor: Huda Salman • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New RA drug enters early safety testing
Disease control Recruiting nowThis early-stage study tests a new drug called LY4213663 in healthy volunteers and people with rheumatoid arthritis (RA). The main goal is to see if the drug is safe and what side effects it may cause. Researchers will also measure how the body processes the drug. The study lasts…
Phase: PHASE1 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New drug hopes to heal painful skin ulcers in rare disease
Disease control Recruiting nowThis study tests whether spesolimab, given as an infusion, can help close skin ulcers in adults with pyoderma gangrenosum, a rare inflammatory skin condition. About 90 participants will receive either spesolimab or a placebo, along with corticosteroids. The trial lasts about 1.5 …
Phase: PHASE3 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New hope for blood cancer patients: experimental drug CCS1477 enters human trials
Disease control Recruiting nowThis study tests a new drug called CCS1477 (inobrodib) in people with advanced blood cancers like leukemia, lymphoma, and myeloma that have not responded to standard treatments. The drug is given as an oral capsule, either alone or combined with other cancer medicines. The goal i…
Phase: PHASE1, PHASE2 • Sponsor: CellCentric Ltd. • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New daily pill could tame bone sarcomas
Disease control Recruiting nowThis phase 2 trial tests a daily oral drug called zanzalintinib in 70 adults with advanced or metastatic bone sarcomas that cannot be removed by surgery. The study includes four groups based on sarcoma type. Researchers will check if the drug is safe and helps control the cancer.
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New hope for kids with arthritis: baricitinib Long-Term trial underway
Disease control Recruiting nowThis study looks at the long-term safety and effectiveness of the drug baricitinib for children aged 1 to 17 with juvenile idiopathic arthritis (JIA). It includes 190 participants who have already taken baricitinib in a previous study. Researchers will monitor side effects and ho…
Phase: PHASE3 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Could a single infusion of modified immune cells tame lupus kidney flares?
Disease control Recruiting nowThis study tests a one-time treatment called Obe-cel, made from a patient's own immune cells, for severe lupus nephritis that hasn't improved with standard care. About 35 people aged 12 to 65 will receive the infusion and be monitored for up to 24 months. The main goal is to see …
Phase: PHASE2 • Sponsor: Autolus Limited • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New drug rebecsinib enters human testing for tough blood cancers
Disease control Recruiting nowThis early-phase study is testing a new drug called rebecsinib in 28 people whose secondary acute myeloid leukemia or high-risk myelofibrosis has come back or not responded to treatment. The drug is given by IV infusion four times per 28-day cycle for up to six cycles. The main g…
Phase: PHASE1 • Sponsor: Aspera Biomedicines, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New drug takes aim at autoimmune diseases in early human test
Disease control Recruiting nowThis early-stage study tests an experimental drug called LY4298445 in healthy volunteers and people with lupus or rheumatoid arthritis. The main goal is to check safety and how the body handles the drug. Participants will receive either the drug or a placebo, and the study lasts …
Phase: PHASE1 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New cell therapy aims to make stem cell transplants safer for blood cancer patients
Disease control Recruiting nowThis phase 2 trial is testing a new treatment called Orca-T for people with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). Orca-T is a personalized cell therapy made from a donor's blood that includes stem cells and immune cells. The goal is to see if it can impr…
Phase: PHASE2 • Sponsor: Orca Biosystems, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New lupus drug aims to cut steroid use in italian patients
Disease control Recruiting nowThis study follows 218 adults with systemic lupus erythematosus (SLE) in Italy who are starting anifrolumab (Saphnelo) for the first time. Researchers want to see if the drug helps patients reach a state of low disease activity while taking 5 mg or less of steroids daily. The stu…
Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New drug trial aims to tame overactive immune system in lupus patients
Disease control Recruiting nowThis early-stage study tests a new drug (GSK5926371) in people with lupus and similar autoimmune diseases. The drug is designed to target and calm specific immune cells that attack the body. The main goal is to check if the drug is safe and how the body handles it, with 54 adults…
Phase: PHASE1 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Double whammy for AFib: single procedure aims to fix rhythm and prevent strokes
Disease control Recruiting nowThis study tests doing two heart procedures at the same time for people with atrial fibrillation. First, doctors use pulsed field energy to fix the heart's rhythm. Then, they implant a small device to close off a part of the heart where clots can form. The goal is to see if this …
Sponsor: Boston Scientific Corporation • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New hope for arthritis sufferers: experimental drugs enter human trials
Disease control Recruiting nowThis phase 2 study tests two experimental drugs, lutikizumab and ravagalimab, alone or together, in about 180 adults with moderate-to-severe rheumatoid arthritis who have not improved with other treatments. The goal is to see if these drugs can reduce joint pain and swelling bett…
Phase: PHASE2 • Sponsor: AbbVie • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New shot every 3 months could ease acromegaly treatment
Disease control Recruiting nowThis phase 3 trial tests a new long-acting version of the drug octreotide (Debio 4126) for people with acromegaly, a condition caused by too much growth hormone. The drug is given as a shot every 12 weeks, instead of the usual monthly injections. The study will compare it to a pl…
Phase: PHASE3 • Sponsor: Debiopharm International SA • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Engineered immune cells take on Hard-to-Treat sarcomas
Disease control Recruiting nowThis early-stage trial is testing a combination of specially engineered immune cells (CAR T cells) and a vaccine for people with sarcoma that has come back or spread. The goal is to see if the treatment is safe and can help shrink tumors. About 20 participants will receive the th…
Phase: PHASE1, PHASE2 • Sponsor: Shenzhen Geno-Immune Medical Institute • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New lupus drug anifrolumab put to the test in everyday clinics
Disease control Recruiting nowThis study is tracking 125 adults with lupus who are starting a new drug called anifrolumab, given as a shot under the skin. Researchers want to see how many patients achieve remission (no active disease) after 24 months of treatment in real-world clinics, not just in strict rese…
Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Could a drug help AML patients fight Chemo-Related anemia?
Disease control Recruiting nowThis trial investigates whether luspatercept can treat anemia caused by chemotherapy in adults with low-risk acute myeloid leukemia (AML). Participants receive luspatercept injections after chemotherapy, and researchers monitor hemoglobin levels and safety. The study aims to find…
Phase: PHASE1, PHASE2 • Sponsor: Guangdong Second Provincial General Hospital • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New drug combo aims to keep High-Risk leukemia in remission before transplant
Disease control Recruiting nowThis study tests whether a combination of venetoclax and azacitidine works better than standard chemotherapy to keep high-risk acute myeloid leukemia (AML) from coming back before a stem cell transplant. About 216 adults who have already achieved remission after initial treatment…
Phase: PHASE2 • Sponsor: The First Affiliated Hospital of Soochow University • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New drug BL-M11D1 takes aim at tough leukemia in early trial
Disease control Recruiting nowThis early-phase trial is testing a new drug called BL-M11D1 in 120 adults with acute myeloid leukemia that has come back or not responded to standard treatments. The drug is designed to target and deliver a toxin directly to leukemia cells. The main goals are to check safety, fi…
Phase: PHASE1 • Sponsor: SystImmune Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New combo therapy targets tough leukemia in older patients
Disease control Recruiting nowThis early-phase trial is testing whether adding the drug daratumumab to standard chemotherapy can help adults aged 60 and older with a high-risk form of acute myeloid leukemia (AML). The main goal is to find the safest dose of daratumumab when given alongside chemotherapy. The s…
Phase: PHASE1 • Sponsor: Nantes University Hospital • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New CAR t combo takes on tough leukemia
Disease control Recruiting nowThis early-phase trial tests a combination of CAR T cells that target three different markers (CLL-1, CD33, and CD123) on leukemia cells in patients with relapsed or refractory acute myeloid leukemia. The study aims to see if this approach is safe and can shrink tumors. Only 10 p…
Phase: PHASE1, PHASE2 • Sponsor: Shenzhen Geno-Immune Medical Institute • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New drug MK-1045 enters early human testing for lupus and RA
Disease control Recruiting nowThis early study tests a new medicine, MK-1045, in about 21 people with lupus or rheumatoid arthritis. The main goal is to see if it is safe and tolerable at different dose levels. Participants receive the drug through an IV infusion, and researchers monitor for side effects.
Phase: PHASE1 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New hope for myelofibrosis: experimental combo targets Drug-Resistant patients
Disease control Recruiting nowThis early-stage trial is testing whether adding roginolisib to the standard drug ruxolitinib is safe and tolerable for adults with myelofibrosis whose disease no longer responds to JAK inhibitors. The study will enroll 26 participants and monitor side effects, heart changes, and…
Phase: PHASE1, PHASE2 • Sponsor: iOnctura • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New hope for Still's disease: experimental drug enters Mid-Stage trial
Disease control Recruiting nowThis study tests a new medicine called MAS825 for people with Still's disease, a rare inflammatory condition causing fever, rash, and joint pain. About 20 children and adults with active disease will receive the drug to see if it safely controls symptoms. The goal is to improve d…
Phase: PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
Engineered immune cells take aim at stubborn leukemia
Disease control Recruiting nowThis phase 1 trial tests a new type of immunotherapy called universal CAR T cells in people with acute myeloid leukemia (AML) that has come back or not responded to treatment. The cells are engineered to recognize and attack leukemia cells by targeting four different proteins (CL…
Phase: PHASE1 • Sponsor: Shenzhen Geno-Immune Medical Institute • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
Less neck surgery may spare shoulder function in oral cancer patients
Disease control Recruiting nowThis study tests whether a less invasive surgery called sentinel lymph node biopsy can replace standard neck dissection for early-stage oral cavity cancer. About 686 patients will be randomly assigned to one of the two procedures. The goal is to see if the gentler approach mainta…
Phase: PHASE2, PHASE3 • Sponsor: NRG Oncology • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
Engineered immune cells take on Hard-to-Treat sarcomas
Disease control Recruiting nowThis trial tests a 4th-generation safety-engineered CAR T cell therapy for people with relapsed or late-stage sarcomas, including osteosarcoma and Ewing sarcoma. Participants receive a single infusion of these immune cells designed to target and attack sarcoma cells. The study ai…
Phase: PHASE1, PHASE2 • Sponsor: Shenzhen Geno-Immune Medical Institute • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
Engineered immune cells take on tough leukemia in early trial
Disease control Recruiting nowThis early-stage trial tests a new treatment called ICG415 CAR-T cells for adults with acute myeloid leukemia that has come back or not responded to standard therapy. The treatment involves taking a patient's own immune cells, engineering them to recognize and attack leukemia cel…
Phase: PHASE1 • Sponsor: iCell Gene Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New combo therapy targets tough leukemia mutations
Disease control Recruiting nowThis early-stage trial tests whether combining the drugs gilteritinib with ivosidenib or enasidenib is safe for people with acute myeloid leukemia (AML) that has returned or not responded to treatment. Participants must have specific gene mutations (FLT3 and IDH1 or FLT3 and IDH2…
Phase: PHASE1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
Radioactive antibody targets cancer before stem cell transplant in High-Risk leukemia trial
Disease control Recruiting nowThis study tests a radioactive antibody (211At-BC8-B10) that seeks out and attacks cancer cells, followed by a donor stem cell transplant for people with high-risk leukemia or myelodysplastic syndrome (MDS) that has returned or not responded to treatment. The goal is to find the …
Phase: PHASE1, PHASE2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New hope for advanced blood cancers: experimental drug EP0042 enters human testing
Disease control Recruiting nowThis study tests a new experimental drug called EP0042 in adults with advanced acute myeloid leukemia (AML) or related blood cancers. The goal is to find a safe dose that might work against the cancer, either alone or with other treatments. About 70 participants will take part to…
Phase: PHASE1, PHASE2 • Sponsor: Ellipses Pharma • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
Can an IV drip replace the needle for arthritis patients?
Disease control Recruiting nowThis study compares two ways of giving the drug bimekizumab to people with active psoriatic arthritis or axial spondyloarthritis: as an IV infusion or as a shot under the skin. The goal is to see if the IV method works just as well as the shot. About 392 adults who are suitable f…
Phase: PHASE1 • Sponsor: UCB Biopharma SRL • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New CAR t cell therapy targets Tough-to-Treat leukemia
Disease control Recruiting nowThis early-stage trial tests a new treatment called CD371-YSNVZ-IL18 CAR T cells for people with acute myeloid leukemia (AML) that has come back or not responded to standard therapy. The main goal is to find the safest dose and see what side effects occur. About 15 participants w…
Phase: PHASE1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New Antibody-Drug conjugate enters human trials for advanced cancers
Disease control Recruiting nowThis early-stage trial tests IM-1021, an antibody-drug conjugate designed to deliver a cancer-killing drug directly to tumor cells. It enrolls 117 adults with advanced solid tumors or B-cell lymphomas that have not responded to standard treatments. The main goals are to check saf…
Phase: PHASE1 • Sponsor: Immunome, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New hope for AML patients: quizartinib maintenance trial launches
Disease control Recruiting nowThis study tests two different doses of the drug quizartinib as a maintenance therapy for adults with a specific type of acute myeloid leukemia (FLT3-ITD positive) who are in their first complete remission after initial treatment and have not had a stem cell transplant. The goal …
Phase: PHASE2 • Sponsor: Daiichi Sankyo • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New drug aims to reverse bone marrow scarring in rare blood cancer
Disease control Recruiting nowThis phase 2 trial tests the drug pacritinib in 30 people with myelofibrosis, a rare bone marrow cancer, who also have low platelet counts. The goal is to see if pacritinib can reduce scarring (fibrosis) in the bone marrow and improve symptoms. Participants take pacritinib pills …
Phase: PHASE2 • Sponsor: Grupo Español de Enfermedades Mieloproliferativas Crónicas PH Negativas • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New hope for kids with arthritis: drug trial launches
Disease control Recruiting nowThis study tests a drug called bimekizumab in children aged 2 to 17 with specific types of juvenile arthritis (enthesitis-related arthritis and juvenile psoriatic arthritis). The goal is to see how the drug moves through the body and if it is safe. About 40 children will take par…
Phase: PHASE3 • Sponsor: UCB Biopharma SRL • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
Immune cell therapy takes on tough scleroderma
Disease control Recruiting nowThis early trial tests whether a single infusion of anti-CD19 CAR T-cells can improve skin thickening and other symptoms in 6 adults with severe, treatment-resistant systemic sclerosis. Participants receive chemotherapy before the infusion and are monitored for 24 months. The stu…
Phase: PHASE2 • Sponsor: University Hospital, Montpellier • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New drug duo targets hard-to-treat leukemias in early trial
Disease control Recruiting nowThis study tests whether combining two drugs, revumenib and mezigdomide, is safe for people with specific types of acute leukemia that have returned or not responded to prior therapy. About 52 participants aged 12 and older will take part. The goal is to find the best dose and se…
Phase: PHASE1, PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New drug combo aims to beat tough childhood leukemia
Disease control Recruiting nowThis phase 3 trial tests whether adding the targeted drug inotuzumab ozogamicin to standard chemotherapy and immunotherapy improves outcomes for children and young adults with high-risk B-cell acute lymphoblastic leukemia (B-ALL). The study will enroll about 6,000 participants an…
Phase: PHASE3 • Sponsor: Children's Oncology Group • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New drug tested to protect fertility in women with rare tumors
Disease control Recruiting nowThis study tests the drug nirogacestat in 50 premenopausal women with desmoid tumors (a type of non-cancerous but aggressive growth). The main goal is to see if the drug affects ovarian function, such as menstrual periods and hormone levels. Participants take nirogacestat orally,…
Phase: PHASE4 • Sponsor: SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New drug aims to wake up immune system against Hard-to-Treat leukemia
Disease control Recruiting nowThis early-phase trial tests a drug called CRD3874-SI, which activates the STING pathway to boost the immune system's ability to fight cancer cells. It is for people with acute myeloid leukemia (AML) that has returned or not responded to previous treatments. The main goal is to f…
Phase: PHASE1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New drug aims to keep AML away after transplant
Disease control Recruiting nowThis Phase 3 trial tests whether mocravimod, taken as a pill, can prevent acute myeloid leukemia (AML) from returning after a stem cell transplant. About 366 adults with high-risk AML will receive either mocravimod or a placebo for up to two years. The main goal is to see if the …
Phase: PHASE3 • Sponsor: Priothera SAS • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New pill targets hard-to-treat blood cancers in early trial
Disease control Recruiting nowThis early-stage study tests a new oral drug called onvansertib for people with chronic myelomonocytic leukemia (CMML) or related blood cancers that have returned or stopped responding to standard treatments. The drug works by blocking a protein that helps cancer cells grow. The …
Phase: PHASE1 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New lupus drug candidate enters first human tests
Disease control Recruiting nowThis early-stage trial is testing a new drug called GSK4527363 in healthy volunteers and people with active lupus or lupus-related lung disease. The main goal is to check safety and how the body handles the drug. Around 142 participants will take part across four groups, includin…
Phase: PHASE1 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New shot aims to keep pericarditis Flare-Ups at bay
Disease control Recruiting nowThis study tests a new drug called KPL-387 in 80 people with well-controlled recurrent pericarditis (inflammation around the heart). The goal is to see if patients can safely switch from their current treatments to KPL-387 alone and still prevent flare-ups. The trial will measure…
Phase: PHASE2 • Sponsor: Kiniksa Pharmaceuticals International, plc • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Radioactive antibody could boost stem cell transplant success in tough leukemias
Disease control Recruiting nowThis study is testing a new approach for people with high-risk acute leukemias or myelodysplastic syndrome. Before a donor stem cell transplant, patients receive a radioactive antibody (211At-BC8-B10) designed to target and kill cancer cells while sparing healthy tissue. The goal…
Phase: PHASE1, PHASE2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New hope for sarcoma patients: drug combo aims to shrink tumors
Disease control Recruiting nowThis study tests a new two-drug treatment for people with advanced soft tissue sarcomas (cancers of the muscles, fat, or other connective tissues). The drugs, abemaciclib and gemcitabine, work together to stop cancer cells from growing. The trial will compare this new combo to th…
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New hope for lupus patients: drug trial targets kidney damage
Disease control Recruiting nowThis study tests if a new drug called cenerimod can help people with lupus who have active kidney disease (lupus nephritis). About 300 adults will take either cenerimod or a placebo daily for 76 weeks, on top of their usual treatments. The main goal is to see if cenerimod improve…
Phase: PHASE3 • Sponsor: Viatris Innovation GmbH • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Immune cell booster trial offers hope for blood cancer relapse after transplant
Disease control Recruiting nowThis early-stage trial tests a special type of immune cell (CIML NK cells) combined with a low dose of IL-2 in people whose blood cancer (like AML or MDS) came back after a stem cell transplant. The goal is to find a safe dose and see if it can put the cancer back into remission.…
Phase: PHASE1 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Supercharged immune cells aim to stop leukemia relapse
Disease control Recruiting nowThis early-phase trial tests whether specially trained natural killer (NK) cells, called CIML NK cells, along with interleukin-2 (IL-2), can safely prevent leukemia from coming back after a stem cell transplant. The study enrolls 15 adults with high-risk acute myeloid leukemia, m…
Phase: PHASE1 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New shot aims to tame rare autoimmune disease
Disease control Recruiting nowThis early-phase trial tests a new drug called PRO-203, given as a single shot under the skin. First, healthy volunteers will check safety; then, people with systemic sclerosis (a rare autoimmune disease that hardens skin and organs) will receive the drug. The main goal is to see…
Phase: PHASE1, PHASE2 • Sponsor: Prolium Bioscience, Inc • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Experimental drug cocktail targets relapsed leukemia
Disease control Recruiting nowThis early-stage trial tests a new drug, 8-chloro-adenosine, combined with the existing drug venetoclax in 30 adults with acute myeloid leukemia that has come back or not responded to treatment. The main goal is to check safety and find the best dose. Researchers hope this combin…
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug combo aims to keep childhood leukemia at bay after transplant
Disease control Recruiting nowThis phase 1 trial tests the safety and best dose of an oral drug called ASTX727 (a combination of cedazuridine and decitabine) along with filgrastim in children with high-risk acute myeloid leukemia (AML) that has returned or not responded to treatment. All participants have alr…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Experimental combo targets tough blood cancers
Disease control Recruiting nowThis early-phase study tests a new drug called SL-401 combined with two other drugs (azacitidine and venetoclax) in people with certain blood cancers—acute myeloid leukemia, myelodysplastic syndrome, and blastic plasmacytoid dendritic cell neoplasm. The main goal is to find the s…
Phase: PHASE1 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Could a new drug combo beat standard chemo for kids with AML?
Disease control Recruiting nowThis large phase 3 trial is testing whether a new formulation of two chemotherapy drugs (CPX-351) and a targeted drug called gilteritinib can improve outcomes for children and young adults with newly diagnosed acute myeloid leukemia (AML). The study compares these new approaches …
Phase: PHASE3 • Sponsor: Children's Oncology Group • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug trial aims to slow rare Cancer's spread
Disease control Recruiting nowThis study tests a drug called zanzalintinib (XL092) in 29 people with advanced leiomyosarcoma that has spread or cannot be removed by surgery. The drug works by blocking signals that help cancer cells grow. The goal is to see if it can slow the cancer's progression longer than c…
Phase: PHASE2 • Sponsor: Northwestern University • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Can a Tight-Control strategy tame lupus?
Disease control Recruiting nowThis study tests whether a 'treat-to-target' approach—where doctors adjust treatment every 6 weeks to aim for remission—works better than usual care for people with lupus. About 606 participants who are not in remission will be followed for 120 weeks. The goal is to see if this s…
Phase: NA • Sponsor: Heinrich-Heine University, Duesseldorf • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Could a simple injection tame stubborn achilles pain?
Disease control Recruiting nowThis trial investigates whether adding up to three corticosteroid injections to standard exercise therapy improves pain and function in adults with chronic midportion Achilles tendinopathy. Participants receive either the steroid injection or a placebo (lidocaine only), alongside…
Phase: PHASE3 • Sponsor: Erasmus Medical Center • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Engineered immune cells take on autoimmune diseases in first human trial
Disease control Recruiting nowThis early-stage study tests a new treatment called ALLO-329 for people with lupus, myositis, or scleroderma. The therapy uses specially engineered immune cells from a donor to target and calm the overactive immune system. The main goals are to check safety and see if it can impr…
Phase: PHASE1 • Sponsor: Allogene Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug combo aims to beat back relapsed leukemia
Disease control Recruiting nowThis study tests a new chemotherapy drug, L-Annamycin, combined with standard cytarabine in adults with acute myeloid leukemia (AML) that has come back or not responded to first treatment. About 312 participants will receive either the new drug combo or a placebo plus cytarabine.…
Phase: PHASE2, PHASE3 • Sponsor: Moleculin Biotech, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Could a simple ear stimulation device tame psoriatic arthritis?
Disease control Recruiting nowThis study tests whether a non-invasive device that gently stimulates a nerve in the ear can help people with psoriatic arthritis. The device, called taVNS, is used for 20 minutes daily over 10 days. Researchers will measure changes in disease activity, pain, quality of life, and…
Phase: NA • Sponsor: Marmara University • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Breathing in chemo: new hope for lung metastases?
Disease control Recruiting nowThis early-phase study tests a chemotherapy drug (gemcitabine) given as a mist to breathe in. It is for people whose solid tumors have spread to the lungs and who have no standard treatment options. The main goal is to find the safest dose and watch for side effects. Up to 44 par…
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New hope for lupus patients with dangerous low platelet counts
Disease control Recruiting nowThis study tests if the drug sirolimus can help adults with lupus who also have very low platelet counts (a condition called immune thrombocytopenia). Participants will receive either sirolimus or a placebo for 24 weeks, then all will receive sirolimus for another 24 weeks. The g…
Phase: PHASE2, PHASE3 • Sponsor: Chinese SLE Treatment And Research Group • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New antibody cocktail takes on tough lupus kidney disease
Disease control Recruiting nowThis early-stage trial is testing two experimental drugs, vonsetamig and odronextamab, in people with lupus nephritis that has not responded to standard treatments. The main goal is to check safety and side effects over the long term. Researchers will also see if the drugs can he…
Phase: PHASE1 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Immune cell combo targets stubborn leukemia in early trial
Disease control Recruiting nowThis early-phase study tests a new treatment for adults with acute myeloid leukemia (AML) that has come back or not responded to standard therapy. The treatment combines specially trained natural killer (NK) immune cells with a drug called atezolizumab. The main goal is to find a…
Phase: PHASE1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New combo therapy aims to improve AML treatment for patients with specific gene changes
Disease control Recruiting nowThis early-phase trial tests whether adding a menin inhibitor (SNDX-5613) to standard chemotherapy can better control acute myeloid leukemia (AML) in people with certain gene changes (NPM1 or MLL). About 38 newly diagnosed adults will receive the combination to find the safest do…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New pill aims to keep AML away after transplant
Disease control Recruiting nowThis phase 2 study tests whether the drug ivosidenib can help prevent acute myeloid leukemia (AML) from coming back after a stem cell transplant. About 75 adults with a specific IDH1 gene mutation will receive either ivosidenib or a placebo daily. The main goal is to see if the d…
Phase: PHASE2 • Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug miRisten targets Tough-to-Treat leukemia in early trial
Disease control Recruiting nowThis early-phase trial is testing a new drug called miRisten in 12 adults whose acute myeloid leukemia (AML) has come back or not responded to prior treatments. The drug works by blocking a molecule that helps cancer cells grow. The main goal is to check safety and find the best …
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New hope for cancer patients with autoimmune conditions: immune checkpoint inhibitor trial expands access
Disease control Recruiting nowThis study is for people who have both an autoimmune disease (like rheumatoid arthritis, lupus, or multiple sclerosis) and an advanced cancer that has spread or cannot be removed by surgery. It tests the safety and effectiveness of the immunotherapy drug nivolumab, given alone or…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New pill takes aim at genetic weakness in tough blood cancers
Disease control Recruiting nowThis early-phase study is testing an experimental oral drug called AZD3632 in about 84 people with advanced blood cancers (acute leukemias or myelodysplastic syndromes) that have certain genetic changes. The main goals are to check the drug's safety and find the right dose, while…
Phase: PHASE1, PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Promising lupus drug anifrolumab now tested in kids
Disease control Recruiting nowThis phase 3 study tests anifrolumab, a biologic drug given by IV, in 100 children aged 5 to 18 with moderate to severe systemic lupus erythematosus (SLE). Participants continue their standard care and are randomly assigned to receive anifrolumab or a placebo. The goal is to see …
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Heart drug nicorandil tested as new arthritis treatment
Disease control Recruiting nowThis study tests whether nicorandil, a drug usually used for heart conditions, can reduce inflammation and improve symptoms in people with active rheumatoid arthritis. 46 participants will take nicorandil tablets for 3 months. Researchers will measure joint disease activity and p…
Phase: PHASE3 • Sponsor: Tanta University • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New daily pill shows promise for Long-Term psoriatic arthritis control
Disease control Recruiting nowThis study tests the long-term safety and effectiveness of an oral drug called zasocitinib (TAK-279) in adults with active psoriatic arthritis, a condition causing joint pain and skin patches. About 1,182 participants who completed a one-year parent study will take either a lower…
Phase: PHASE3 • Sponsor: Takeda • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Could a daily ultrasound zap arthritis pain at home?
Disease control Recruiting nowThis study tests a non-invasive device that uses ultrasound to stimulate the spleen and reduce inflammation in people with moderate to severe rheumatoid arthritis. About 60 adults who haven't responded well to standard medications will use the device at home for 12 weeks, with so…
Phase: NA • Sponsor: SecondWave Systems Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Experimental drug aims to revive failing cancer fighters in rare sarcomas
Disease control Recruiting nowThis early-phase trial tests an immunotherapy drug called N-803 in up to 8 people with synovial sarcoma or myxoid/round cell liposarcoma whose cancer got worse after a prior cell therapy. N-803 is designed to boost the patient's own immune cells that survived the earlier treatmen…
Phase: EARLY_PHASE1 • Sponsor: Seth Pollack • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Engineered immune cells take on Hard-to-Treat scleroderma in landmark trial
Disease control Recruiting nowThis study tests whether a one-time infusion of specially engineered immune cells (CAR T cells) can improve lung function and skin hardening better than current treatments for people with active systemic sclerosis, a rare autoimmune disease. About 92 adults with lung involvement …
Phase: PHASE3 • Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Could a One-Time cell treatment tame lupus in young patients?
Disease control Recruiting nowThis study tests a new treatment called CART19 for teens and young adults (ages 12-29) with severe lupus that hasn't improved with standard treatments. CART19 uses a patient's own immune cells, modified in a lab to target and calm the overactive immune system causing lupus. The g…
Phase: PHASE1, PHASE2 • Sponsor: Children's Hospital of Philadelphia • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New hope for blood cancer patients: STP938 trial targets tough cases
Disease control Recruiting nowThis Phase 2 trial tests STP938, a daily pill, in 50 adults with high-risk essential thrombocythaemia who cannot use standard therapy. The goal is to see if it safely lowers high platelet counts and reduces complications like blood clots. Participants take the drug for up to 12 m…
Phase: PHASE2 • Sponsor: Step Pharma, SAS • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New pill shows promise for rare joint tumor in early trial
Disease control Recruiting nowThis phase 2 trial tests a daily oral drug called pimicotinib in 20 Japanese adults with tenosynovial giant cell tumor (TGCT) that cannot be removed by surgery. The study aims to see if the drug is safe, how it moves through the body, and whether it shrinks tumors. Participants t…
Phase: PHASE2 • Sponsor: Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New pill could transform leukemia treatment, phase 3 trial begins
Disease control Recruiting nowThis study tests a new oral drug, QTX-2101, combined with standard ATRA therapy for adults newly diagnosed with a low-risk form of acute promyelocytic leukemia (APL). The goal is to see if the oral capsule works as well as the current intravenous treatment. About 150 participants…
Phase: PHASE3 • Sponsor: Quetzal Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Could a cell shot free CML patients from daily pills?
Disease control Recruiting nowThis early-stage trial tests a cell therapy called vididencel in 24 adults with chronic myeloid leukemia (CML) who still have traces of cancer despite taking standard medication. The goal is to see if adding vididencel to their current treatment is safe and might eventually allow…
Phase: PHASE1 • Sponsor: Mendus • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Could a blood clot replace gum surgery for dental implants?
Disease control Recruiting nowThis study compares two methods to improve gum thickness around dental implants in the front of the mouth. One method uses a platelet-rich fibrin (PRF) membrane made from the patient's own blood, while the other uses a standard connective tissue graft. The trial will enroll 26 ad…
Phase: NA • Sponsor: Gulf Medical University • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Gene-Edited cells take on lupus and scleroderma in first human test
Disease control Recruiting nowThis early-stage trial tests a single infusion of CRISPR-edited immune cells (CTX112) from a healthy donor in 80 adults with severe lupus, scleroderma, or myositis that hasn't responded to standard treatments. The goal is to see if the cells are safe and can reduce disease activi…
Phase: PHASE1 • Sponsor: CRISPR Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug BAL0891 enters human trials for Tough-to-Treat cancers
Disease control Recruiting nowThis early-stage study tests a new drug called BAL0891, given alone or with chemotherapy or immunotherapy, in people with advanced solid tumors or acute myeloid leukemia (AML) that has come back or not responded to treatment. The main goals are to find a safe dose and check for s…
Phase: PHASE1 • Sponsor: SillaJen, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New pill targets rare gene mutation in Hard-to-Treat blood cancers
Disease control Recruiting nowThis early-stage trial tests an oral drug called AG-120 in people with advanced blood cancers, like acute myeloid leukemia, that have a specific IDH1 mutation. The study aims to find the safest dose and see if the drug can control the disease. About 291 participants will take the…
Phase: PHASE1 • Sponsor: Institut de Recherches Internationales Servier • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New hope for older leukemia patients: drug combo aims for higher remission
Disease control Recruiting nowThis study tests a new combination of drugs (venetoclax, azacitidine, chidamide, and others) against the standard chemotherapy for adults aged 60-75 with newly diagnosed acute myeloid leukemia (AML). The goal is to see if the new combo leads to more remissions and fewer side effe…
Phase: PHASE2 • Sponsor: Chinese PLA General Hospital • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New pill combo aims to tame bone marrow cancer
Disease control Recruiting nowThis early-phase study tests whether adding a new drug called pelabresib to the standard treatment ruxolitinib is safe and helpful for Japanese adults with myelofibrosis, a type of bone marrow cancer. Only 6 people will take part, and the main goal is to check for side effects an…
Phase: PHASE1 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New gel could heal painful finger sores in rare disease
Disease control Recruiting nowThis early-stage trial tests a new drug called TOP-N53, applied directly to finger ulcers in people with systemic sclerosis (scleroderma). The main goal is to check safety and see if it improves pain and blood flow. Fifteen participants will receive either the drug or a placebo o…
Phase: PHASE2 • Sponsor: Topadur Pharma AG • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New stem cell combo could boost survival in blood cancer patients
Disease control Recruiting nowThis study is testing a new way to do stem cell transplants for people with acute myeloid leukemia (AML) or high-risk myelodysplastic syndromes (MDS). It combines stem cells from a half-matched donor (haploidentical) with cord blood, given at different times. The goal is to help …
Phase: NA • Sponsor: Fujian Medical University Union Hospital • Aim: Disease control
Last updated Jun 27, 2026 13:08 UTC
-
Promising new combo therapy for infant leukemia shows potential
Disease control Recruiting nowThis study tests whether adding two targeted drugs, blinatumomab and venetoclax, to standard chemotherapy can improve outcomes for infants with a type of leukemia called acute lymphoblastic leukemia (ALL). About 153 infants will participate. The goal is to see if these combinatio…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 13:08 UTC
-
Kids with gut or joint inflammation get long-term safety check on biologic drug guselkumab
Disease control Recruiting nowThis study is checking the long-term safety of guselkumab, a biologic drug given as a shot, in children with moderate to severe Crohn's disease, ulcerative colitis, or juvenile psoriatic arthritis. About 196 kids who already completed a prior guselkumab study and benefited from i…
Phase: PHASE3 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jun 27, 2026 13:08 UTC
-
Engineered immune cells take aim at stubborn leukemia
Disease control Recruiting nowThis early-phase trial is testing a new cell therapy called CD83 CAR T cells in 26 adults with acute myeloid leukemia (AML) that has returned or not responded to treatment. The therapy uses a patient's own immune cells, genetically modified to recognize and attack a protein (CD83…
Phase: PHASE1 • Sponsor: Roswell Park Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 13:08 UTC
-
Could a lower dose of a transplant drug be better for blood cancer patients?
Disease control Recruiting nowThis study is testing whether a lower dose of the drug cyclophosphamide, given after a stem cell transplant, can prevent graft-versus-host disease (a common complication where donor cells attack the patient's body) while still being effective. The trial involves 260 adults with b…
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New hope for rare hormone disorder: drug targets Out-of-Control cortisol
Disease control Recruiting nowThis study tests a new drug called Lu AG13909 in 18 adults with Cushing's disease, a rare condition where the body produces too much cortisol. The goal is to see if the drug can safely lower cortisol levels to normal. Participants will receive the drug through an IV or injection,…
Phase: PHASE2 • Sponsor: H. Lundbeck A/S • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
Donor immune cells join fight against Hard-to-Treat leukemia
Disease control Recruiting nowThis early-phase trial tests whether adding natural killer (NK) cells from a healthy donor to the standard drugs azacitidine and venetoclax can help control acute myeloid leukemia (AML). About 32 adults with relapsed or hard-to-treat AML will receive the combination. The main goa…
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
Can a lupus drug help when given early?
Disease control Recruiting nowThis study tests the drug belimumab (Benlysta) in 30 people who were diagnosed with lupus within the last two years. Participants will receive either the drug or a placebo for one year, and then some may switch to placebo in the second year. The goal is to see if early treatment …
Phase: PHASE4 • Sponsor: Northwell Health • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New drug combo targets tough blood cancers in early trial
Disease control Recruiting nowThis early-stage trial is testing a new drug called cirtuvivint, alone or with another drug combo (ASTX727), in people with myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML). The goal is to find the safest dose and check for side effects. About 54 participants whose…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New drug combo aims to outsmart Hard-to-Treat cancers
Disease control Recruiting nowThis early-phase study tests an experimental drug called OKN4395, taken as a pill, alone or together with the immunotherapy pembrolizumab. The goal is to find a safe dose and see if the combination can shrink tumors in people with advanced solid cancers like lung, colorectal, sto…
Phase: PHASE1 • Sponsor: Epkin • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
Drug combo aims to halt lung scarring in scleroderma
Disease control Recruiting nowThis trial tests whether adding rituximab to standard mycophenolate mofetil (MMF) therapy can improve lung function in people with severe lung scarring caused by systemic sclerosis. About 102 adults with this condition will receive either rituximab infusions plus MMF or placebo i…
Phase: PHASE3 • Sponsor: University Hospital, Tours • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New hope for rare childhood cancer: drug cocktail aims to shrink tumors and prevent return
Disease control Recruiting nowThis study is for children and young adults (up to age 30) with a rare type of soft tissue cancer called non-rhabdomyosarcoma. It tests whether adding the drugs pazopanib and selinexor to standard chemotherapy can improve outcomes. Participants receive treatment tailored to their…
Phase: PHASE1, PHASE2 • Sponsor: St. Jude Children's Research Hospital • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New hope for kids with tough leukemia: oral drug combo enters human testing
Disease control Recruiting nowThis early-phase trial is testing a combination of two oral drugs—venetoclax and decitabine/cedazuridine—in children and teens whose acute myeloid leukemia (AML) has returned or not responded to prior treatment. The study aims to find the safest dose and check for early signs tha…
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New hope for kids with tough leukemia: Three-Drug combo trial launches
Disease control Recruiting nowThis early-phase trial tests a combination of three drugs—ziftomenib, venetoclax, and gemtuzumab—in children and young adults (ages 3 to 21) with acute myeloid leukemia that has come back or not responded to treatment. The main goal is to find a safe dose and check for side effec…
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
Immune cell shot aims to tame tough lupus cases
Disease control Recruiting nowThis early-phase trial tests whether adding NK cells (a type of immune cell) to the standard drug rituximab can safely help people with severe lupus or lupus-related kidney disease. The study will enroll 18 adults in China and focus on safety and signs of disease improvement. It …
Phase: PHASE1 • Sponsor: Guangdong Provincial People's Hospital • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New pill could ease juvenile arthritis in kids
Disease control Recruiting nowThis study tests a daily pill called filgotinib in children aged 8 to 17 with a type of arthritis that affects multiple joints. The goal is to see if the drug is safe and helps control the disease over 18 weeks. About 65 participants will take the drug and be monitored for side e…
Phase: PHASE3 • Sponsor: Alfasigma S.p.A. • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
Experimental drug plus radiation shows promise for rare sarcoma
Disease control Recruiting nowThis early-phase trial is testing whether the drug abemaciclib, when given with radiation therapy before surgery, can safely shrink high-risk retroperitoneal liposarcomas. About 18 adults with this rare cancer will receive the combination to find the best dose and check for side …
Phase: PHASE1 • Sponsor: University of Washington • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
Can gentler therapy beat harsh chemo for tough leukemia?
Disease control Recruiting nowThis phase 3 trial tests whether less intense drug combinations can control relapsed or refractory acute myeloid leukemia (AML) as well as high-dose chemotherapy. About 339 adults whose AML has returned or not responded to initial treatment will be randomly assigned to either a l…
Phase: PHASE3 • Sponsor: Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Leukemia drug Asciminib's Long-Term safety tracked in ongoing study
Disease control Recruiting nowThis study follows people with chronic myeloid leukemia (CML) who have already benefited from the drug asciminib in earlier Novartis trials. Researchers want to see how safe the drug is over the long term. About 347 participants will continue taking asciminib or other similar dru…
Phase: PHASE4 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New drug combo aims to cut steroid use in painful rheumatic condition
Disease control Recruiting nowThis Phase 3 trial tests whether adding baricitinib (a JAK inhibitor pill) to standard steroid treatment can help people with polymyalgia rheumatica achieve disease control without needing long-term steroids. About 140 adults aged 50+ with active PMR will receive baricitinib (2 m…
Phase: PHASE3 • Sponsor: University Hospital, Brest • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New drug cocktail shows promise against tough blood cancers
Disease control Recruiting nowThis study combines three chemotherapy drugs (cladribine, idarubicin, cytarabine) with a targeted drug (quizartinib) to treat acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). It includes up to 80 adults who are newly diagnosed or whose cancer has returne…
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New CML drug asciminib under Real-World study
Disease control Recruiting nowThis study is watching how well asciminib works and how safe it is in adults with a type of blood cancer called chronic myeloid leukemia. It includes people who are newly diagnosed or have already tried one other treatment. The main goal is to see how many patients reach a very l…
Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New hope for psoriatic arthritis sufferers: experimental drug sonelokimab enters final testing phase
Disease control Recruiting nowThis study tests a new drug called sonelokimab for adults with active psoriatic arthritis who have not improved with or cannot take standard TNF-blocker medications. About 600 participants will receive either sonelokimab, a placebo, or an existing drug (risankizumab) for comparis…
Phase: PHASE3 • Sponsor: MoonLake Immunotherapeutics AG • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Engineered virus targets Hard-to-Treat blood cancers in new trial
Disease control Recruiting nowThis early-phase trial tests a genetically modified virus (VSV-IFNβ-NIS) alone or with chemotherapy and immunotherapy drugs in people with blood cancers like multiple myeloma, acute myeloid leukemia, and lymphomas that have returned or not responded to treatment. The virus is des…
Phase: PHASE1 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Experimental drug plus radiation aims to tackle returning head and neck cancers
Disease control Recruiting nowThis early-phase trial is testing whether a drug called camonsertib, combined with a precise type of radiation, can help control head and neck cancers that have come back or cannot be removed by surgery. About 39 adults with these cancers will receive the drug along with focused …
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
CAR-T therapy takes on lupus and scleroderma in early trial
Disease control Recruiting nowThis early-phase trial is testing a new treatment called zamto-cel, a CAR-T cell therapy, for people with severe lupus or scleroderma that hasn't improved with standard treatments. The study will enroll 48 participants and primarily look at safety and side effects. Participants f…
Phase: PHASE1 • Sponsor: Miltenyi Biomedicine GmbH • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Triple drug cocktail targets tough leukemia
Disease control Recruiting nowThis study tests a combination of three drugs—ASTX727, venetoclax, and gilteritinib—for people with acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome that has a FLT3 mutation. The drugs work in different ways to stop cancer cells from growing. The trial aims to f…
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Engineered immune cells take on muscle disease
Disease control Recruiting nowThis study tests a one-time treatment called CABA-201, made from a patient's own immune cells, for people with active inflammatory muscle diseases like dermatomyositis. The therapy aims to reset the immune system by targeting and removing certain immune cells. Researchers will ch…
Phase: PHASE2, PHASE3 • Sponsor: Cabaletta Bio • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New drug cocktail targets rare, aggressive cancer
Disease control Recruiting nowThis phase 2 trial is testing whether combining two chemotherapy drugs—Abraxane and liposomal doxorubicin—can shrink tumors in people with advanced or unresectable angiosarcoma, a rare and aggressive cancer of blood vessels. The study will enroll 69 patients who have already trie…
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New injection could unclench curved fingers
Disease control Recruiting nowThis study tests a new drug called CNT201 for people with Dupuytren's contracture, a condition where fingers bend toward the palm and can't straighten. The drug is injected into the tight cord in the finger to break it down, aiming to restore movement. About 60 adults aged 18 to …
Phase: PHASE1, PHASE2 • Sponsor: CONNEXT • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New hope for kids with tough leukemia: experimental drug enters human testing
Disease control Recruiting nowThis early-stage study is testing an experimental drug called pivekimab sunirine in about 18 children whose acute myeloid leukemia (AML) has come back or not responded to standard treatments. The main goals are to check the drug's safety and how it moves through the body. Partici…
Phase: PHASE1 • Sponsor: AbbVie • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Engineered immune cells take aim at Hard-to-Treat lupus
Disease control Recruiting nowThis study tests a new treatment called AZD0120 for people with severe lupus that hasn't improved with standard therapies. AZD0120 is a type of CAR T cell therapy that targets two proteins (CD19 and BCMA) on immune cells to calm the overactive immune system. The trial will enroll…
Phase: PHASE1, PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Could a probiotic tame rheumatoid arthritis? early trial begins
Disease control Recruiting nowThis early-stage study is testing whether an oral probiotic called R-2487 is safe for people with rheumatoid arthritis. Researchers will also check if it reduces joint swelling and inflammation. The trial involves 73 adults with active RA who will take the probiotic and be monito…
Phase: PHASE1 • Sponsor: Rise Therapeutics LLC • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Weight-Loss drug added to arthritis therapy shows promise in new trial
Disease control Recruiting nowThis study looks at whether adding tirzepatide (a weight-loss drug) to standard ixekizumab treatment helps adults with active psoriatic arthritis who are overweight or obese. About 200 participants will receive both medications for up to 12 months. The goal is to see if this comb…
Phase: PHASE4 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Engineered immune cells take aim at Hard-to-Treat leukemia
Disease control Recruiting nowThis study tests a new treatment for people with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) that has come back or not responded to standard therapy. The treatment uses specially engineered natural killer (NK) cells designed to recognize and attack cancer cells…
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
New drug cocktail targets tough blood cancers
Disease control Recruiting nowThis study tests a combination of two drugs, CPX-351 and ivosidenib, in about 30 adults with a specific genetic form of acute myeloid leukemia or high-risk myelodysplastic syndrome. The goal is to see if the combo can shrink or control the cancer. Participants must have the IDH1 …
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
New combo therapy aims to boost remission in IDH2-Mutated AML
Disease control Recruiting nowThis phase II trial tests whether adding enasidenib to standard ASTX727 and venetoclax improves remission rates in older adults (or younger unfit patients) with newly diagnosed IDH2-mutated acute myeloid leukemia (AML). About 93 participants will be randomly assigned to receive e…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
New hope for CML patients: asciminib trial targets treatment failures
Disease control Recruiting nowThis phase 2 study tests asciminib, a daily pill, in 40 adults with chronic myeloid leukemia whose first treatment with a TKI drug didn't work or caused side effects. Participants take asciminib for up to 2 years. The main goal is to see how many achieve a major molecular respons…
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
New combo therapy aims to improve leukemia outcomes in older adults
Disease control Recruiting nowThis Phase 2 trial tests whether adding venetoclax to a chemotherapy regimen of cladribine, low dose cytarabine, and azacitidine can improve remission rates in adults aged 50 and older with untreated acute myeloid leukemia. The study involves 145 participants and uses a two-stage…
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
Could a COPD drug ease rheumatoid arthritis?
Disease control Recruiting nowThis study tests whether adding roflumilast to standard treatment can reduce joint pain and swelling in people with active rheumatoid arthritis. About 50 adults aged 18-60 will take either roflumilast or a placebo for 12 weeks. Researchers will measure changes in disease activity…
Phase: PHASE2 • Sponsor: Horus University • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
New pill shows promise for Hard-to-Treat leukemia
Disease control Recruiting nowThis study tests a new oral drug called bleximenib for people with acute leukemia that has come back or not responded to treatment. The drug targets specific genetic changes in the cancer cells. The trial has two phases: first to find the safest dose, then to see how well it work…
Phase: PHASE1, PHASE2 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
New shot aims to stop repeat heart sac inflammation
Disease control Recruiting nowThis study tests an injected drug called KPL-387 in 165 people with recurrent pericarditis, a condition where the sac around the heart becomes inflamed again and again. The goal is to see if KPL-387 can reduce flare-ups and pain better than a placebo. Participants must have sympt…
Phase: PHASE2, PHASE3 • Sponsor: Kiniksa Pharmaceuticals International, plc • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
Allergy drug could help rheumatoid arthritis patients
Disease control Recruiting nowThis phase 2 trial is testing whether adding desloratadine, an allergy medication, to standard rheumatoid arthritis therapy can reduce joint inflammation and disease activity. Sixty adults with active RA will receive either desloratadine or a placebo for 12 weeks. The study measu…
Phase: PHASE2 • Sponsor: Horus University • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
New pill could tame skin lupus flares
Disease control Recruiting nowThis study tests an oral medication called ICP-488 for people with cutaneous lupus erythematosus (CLE), a condition that causes painful skin rashes and lesions. About 105 adults aged 18–75 with moderate-to-severe CLE will receive either the drug or a placebo for 16 weeks. The mai…
Phase: PHASE2 • Sponsor: Beijing InnoCare Pharma Tech Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
New triple therapy offers hope for AML patients
Disease control Recruiting nowThis study tests a new combination of three drugs (venetoclax, azacitidine, and liposomal mitoxantrone) as the first treatment for adults with newly diagnosed acute myeloid leukemia (AML). About 30 participants will receive this therapy, followed by standard chemotherapy and, for…
Phase: NA • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
New drug combo aims to control tough leukemia
Disease control Recruiting nowThis study tests whether combining two drugs, blinatumomab and asciminib, can help control Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). The trial enrolls 40 adults who are not good candidates for strong chemotherapy. Researchers will monitor safety and…
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New hope for leukemia patients: asciminib trial launches
Disease control Recruiting nowThis Phase 2 trial tests the drug asciminib in 50 adults newly diagnosed with chronic myeloid leukemia (CML). The goal is to see if asciminib can control the disease and to check for side effects. Participants take the drug by mouth, and researchers monitor their health closely.
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
Supercharged immune cells take on tough blood cancers
Disease control Recruiting nowThis study tests a new treatment for people with blood cancers like leukemia, lymphoma, and multiple myeloma that have returned or not responded to treatment. Participants receive chemotherapy followed by specially engineered natural killer (NK) cells from donated cord blood. The…
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New drug GS-0151 tested for rheumatoid arthritis in early trial
Disease control Recruiting nowThis early-stage trial is testing a new drug called GS-0151 in 75 adults with rheumatoid arthritis. The main goal is to see if the drug is safe and how the body processes it. Participants will receive either GS-0151 or a placebo for 12 weeks.
Phase: PHASE1 • Sponsor: Gilead Sciences • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New shoulder implant under Long-Term watch: will it hold up?
Disease control Recruiting nowThis study follows 50 people who receive a Zimmer Biomet shoulder replacement implant to see if it safely improves pain, movement, and quality of life over two years. Participants have shoulder arthritis, fractures, or other joint damage. The main goal is to measure a meaningful …
Sponsor: Zimmer Biomet • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New study tracks ilaris use in rare inflammatory diseases across europe
Disease control Recruiting nowThis study looks at how patients with Familial Mediterranean Fever (FMF) and Still's disease (including systemic juvenile idiopathic arthritis and adult-onset Still's disease) use the drug canakinumab (Ilaris) over the long term. Researchers will track 160 patients across Europe …
Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New hope for rare blood cancers: first human trial of PRT12396 begins
Disease control Recruiting nowThis early-stage study tests a new drug, PRT12396, in about 100 people with polycythemia vera or myelofibrosis—rare blood cancers. The main goals are to find a safe dose and check for side effects. Researchers will also look for signs that the drug controls the disease, but this …
Phase: PHASE1 • Sponsor: Prelude Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New RA drug BMS-986454 enters early human testing
Disease control Recruiting nowThis early-phase trial is testing a new drug called BMS-986454 in 46 adults with rheumatoid arthritis who did not fully respond to methotrexate. The main goal is to check the drug's safety, tolerability, and how it moves through the body. Participants will receive either the drug…
Phase: PHASE1 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New drug cocktail aims to control aggressive blood cancers
Disease control Recruiting nowThis study tests whether alternating two different drug combinations can help control higher-risk myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML). About 60 adults who have not responded to or relapsed after standard treatment will receive cladribine, low…
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
Boosting transplants with donor immune cells to fight blood cancer relapse
Disease control Recruiting nowThis study tests whether giving donor white blood cells (lymphocytes) soon after a stem cell transplant can lower the chance of cancer returning in people with high-risk blood cancers like leukemia or lymphoma. Participants receive chemotherapy, a stem cell transplant, and then a…
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New lupus drug CLN-978 enters early human testing
Disease control Recruiting nowThis early-stage study tests a new drug called CLN-978 in 24 people with moderate to severe lupus. The main goal is to see if the drug is safe and tolerable. Researchers will also measure how the drug moves through the body and how it affects immune cells. This is a first step to…
Phase: PHASE1 • Sponsor: Cullinan Therapeutics Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
New antibody therapy targets rare blood cancers in first human trial
Disease control Recruiting nowThis early-stage study tests a new drug called JNJ-88549968, a bispecific antibody designed to direct the body's immune T cells to attack cancer cells with a specific CALR mutation. The trial will enroll about 220 adults with essential thrombocythemia or myelofibrosis who carry t…
Phase: PHASE1 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
Promising new combo targets hard-to-treat leukemia mutations
Disease control Recruiting nowThis study tests whether adding the experimental drug bleximenib to standard treatment (venetoclax and azacitidine) helps people with a specific genetic subtype of acute myeloid leukemia (AML) achieve remission and live longer. The trial enrolls 600 adults aged 18 and older who h…
Phase: PHASE3 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
Immune cell therapy takes on autoimmune diseases
Disease control Recruiting nowThis study tests a new treatment called NKX019 for people with autoimmune diseases like systemic sclerosis, rheumatoid arthritis, and vasculitis. NKX019 uses specially engineered immune cells to target and calm overactive B cells that cause the disease. The goal is to see if it i…
Phase: PHASE1, PHASE2 • Sponsor: Nkarta, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
New oral cocktail aims to tame tough leukemia
Disease control Recruiting nowThis study tests a new all-oral combination of three drugs—SNDX-5613, ASTX727, and venetoclax—for people with acute myeloid leukemia (AML) or related leukemia. The first part finds the safest dose of SNDX-5613, and the second part checks if that dose helps control the disease. Ab…
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
Could amniotic membrane ease bladder pain? new trial seeks answers
Disease control Recruiting nowThis study tests whether injecting a substance made from donated amniotic membrane into the bladder can reduce pain and urgency in women with interstitial cystitis (painful bladder syndrome). One hundred women who have not gotten better with other treatments will receive either t…
Phase: PHASE2, PHASE3 • Sponsor: David Sheyn • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
New hope for tough blood cancers? early trial launches
Disease control Recruiting nowThis early-stage trial is testing an experimental drug called JNJ-95804306 in people with blood cancers like leukemia that have come back or not responded to standard treatments. The study has two parts: first, finding a safe dose, and then checking if the drug shrinks tumors whe…
Phase: PHASE1 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
Experimental mRNA CAR-T therapy targets autoimmune diseases in first human trial
Disease control Recruiting nowThis early-phase trial tests Arnovie101, an mRNA-based CAR-T therapy given directly into the bloodstream, in 5 people with lupus or autoimmune hemolytic anemia. The goal is to see if it is safe and how the body processes it. Researchers will also check if it reduces disease activ…
Phase: EARLY_PHASE1 • Sponsor: Circunited BioPharma (Shenzhen) Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
Cord blood transplants made more accessible for thousands with blood cancers
Disease control Recruiting nowThis study provides unlicensed cord blood units for transplant to children and adults with blood cancers, immune disorders, and other serious diseases. The goal is to see how well patients recover their white blood cells after the transplant. By making more cord blood units avail…
Sponsor: Center for International Blood and Marrow Transplant Research • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
Can a night-time breathing device boost brain power in older vets with lung and sleep troubles?
Disease control Recruiting nowThis study looks at whether using a positive airway pressure (PAP) machine at night can improve thinking, sleepiness, and quality of life in older veterans (age 60+) who have both COPD and obstructive sleep apnea—a combination called Overlap Syndrome. About 668 participants will …
Phase: NA • Sponsor: VA Office of Research and Development • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
New drug trial aims to tame hardening skin and lung damage in scleroderma
Disease control Recruiting nowThis study tests whether the drug ianalumab can help people with diffuse cutaneous systemic sclerosis, a condition that causes skin thickening and can damage internal organs like the lungs. About 200 adults will receive either ianalumab or a placebo as a shot under the skin. Rese…
Phase: PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
New psoriatic arthritis drug shows promise in Mid-Stage trial
Disease control Recruiting nowThis study tests whether the experimental drug JNJ-88545223 can reduce joint pain, swelling, and skin symptoms in adults with active psoriatic arthritis. About 240 participants will receive either the drug or a placebo to see if it works better than no treatment. The goal is to i…
Phase: PHASE2 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
New pill could tame hormone disorder Cushing's syndrome
Disease control Recruiting nowThis early-stage study tests an experimental pill called CRN04894 in 18 adults with Cushing's syndrome caused by too much ACTH hormone. The drug works by blocking the receptor that ACTH acts on, aiming to lower cortisol levels and control the disease. The main goals are to check …
Phase: PHASE1, PHASE2 • Sponsor: Crinetics Pharmaceuticals Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New transplant method aims to cut dangerous side effects in blood cancer patients
Disease control Recruiting nowThis study tests a stem cell transplant method that removes certain immune cells (T-cells and B-cells) from the donor cells. The goal is to reduce graft-versus-host disease, a serious complication where donor cells attack the patient's body. The trial includes 20 children and you…
Phase: PHASE2 • Sponsor: University of Florida • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New hope for indian patients with psoriatic arthritis: guselkumab trial launches
Disease control Recruiting nowThis study tests a drug called guselkumab in 100 Indian adults with psoriatic arthritis, a condition causing joint pain and swelling. Participants must have tried standard treatments without success. The goal is to see if the drug is safe and helps reduce joint symptoms over 12 w…
Phase: PHASE4 • Sponsor: Johnson & Johnson Private Limited • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
Could a common drug improve stem cell transplants for a rare bone marrow cancer?
Disease control Recruiting nowThis early-phase study tests whether adding pegylated interferon alfa-2a after a stem cell transplant can help control myelofibrosis, a type of bone marrow cancer. About 18 adults with primary or secondary myelofibrosis will receive the drug after their transplant to find the saf…
Phase: PHASE1 • Sponsor: University of Utah • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
Ultrasound study to see if guselkumab eases psoriatic arthritis
Disease control Recruiting nowThis study is testing how well the drug guselkumab works for people with psoriatic arthritis, a condition that causes joint pain and skin patches. Researchers will use ultrasound to measure joint inflammation in 200 participants over 24 weeks. The goal is to see if guselkumab red…
Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New hope for tough blood cancers: experimental drug JNJ-90189892 enters human testing
Disease control Recruiting nowThis early-stage trial is testing an experimental drug called JNJ-90189892 in about 155 people with acute myeloid leukemia (AML) or myelodysplastic neoplasms (MDS) that have come back or not responded to treatment. The study has several parts: first, finding a safe dose of JNJ-90…
Phase: PHASE1 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New drug trial hopes to thicken skin Disease's fate
Disease control Recruiting nowThis study tests an experimental drug called MTX-474 in 85 people with diffuse cutaneous systemic sclerosis, a condition that causes skin thickening and organ damage. Participants will receive either MTX-474 or a placebo for 24 weeks to see if the drug safely reduces skin thickne…
Phase: PHASE2 • Sponsor: Mediar Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New study tracks arthritis drug persistence in daily life
Disease control Recruiting nowThis study follows 200 adults with psoriatic arthritis who are starting guselkumab as part of their normal care. Researchers will track how many patients continue the treatment after one and two years, and why some stop. The goal is to understand how well the drug works in real-w…
Sponsor: Janssen-Cilag Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New drug nipocalimab aims to tame lupus in major trial
Disease control Recruiting nowThis phase 3 study tests whether nipocalimab can help control moderate to severe systemic lupus erythematosus (SLE), a chronic autoimmune disease. About 600 adults will receive either nipocalimab or a placebo, on top of standard treatments. The main goal is to see if more people …
Phase: PHASE3 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New pill could ease psoriatic arthritis pain
Disease control Recruiting nowThis study tests a new drug called icotrokinra (JNJ-77242113) for people with active psoriatic arthritis. About 750 adults who have tried other treatments will receive either the drug or a placebo. The goal is to see if the drug reduces joint pain and skin symptoms better than a …
Phase: PHASE3 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
Lupus patients get hope from Cancer-Fighting cell therapy
Disease control Recruiting nowThis early-phase trial is testing a new treatment called GC012F (CD19-BCMA CAR-T cells) for people with severe lupus that hasn't improved with standard medications. The therapy uses a patient's own immune cells, modified to target and destroy faulty B cells driving the disease. T…
Phase: EARLY_PHASE1 • Sponsor: RenJi Hospital • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
Experimental CAR-T therapy takes on tough leukemia
Disease control Recruiting nowThis early-stage trial is testing a new type of CAR-T cell therapy, called CT0890B, for people with acute myeloid leukemia (AML) that has come back or not responded to treatment. The therapy uses donor-derived immune cells that are engineered to target a protein called NKG2DL on …
Phase: PHASE1 • Sponsor: Peking University People's Hospital • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New hope for tough leukemia: drug combo trial launches
Disease control Recruiting nowThis study tests a combination of two drugs, azacitidine (a standard chemotherapy) and APG1252 (a new targeted therapy), in people with high-risk acute myeloid leukemia (AML). The goal is to see if the combo is safe and can help control the disease. About 52 participants will be …
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
Engineered immune cells take on lupus and other autoimmune diseases
Disease control Recruiting nowThis early-stage trial is testing a new treatment called CC-97540, which uses a patient's own immune cells modified to target and destroy faulty immune cells. It is for people with severe forms of lupus, myositis, scleroderma, or rheumatoid arthritis that have not improved with s…
Phase: PHASE1 • Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
New study tests belimumab to tame early lupus
Disease control Recruiting nowThis study is testing the drug belimumab (Benlysta) in 350 adults who were diagnosed with systemic lupus erythematosus (SLE) within the last two years and still have active disease despite standard treatment. The goal is to see if adding belimumab helps more people reach a state …
Phase: PHASE4 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
New antibody GEN3018 enters first human tests for tough blood cancers
Disease control Recruiting nowThis early-stage trial is testing a new antibody drug called GEN3018 in people whose acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS) has come back or stopped responding to treatment. The main goal is to check safety and find the right dose. Up to 78 parti…
Phase: PHASE1 • Sponsor: Genmab • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
Lupus patients may get new hope from In-Body cell therapy
Disease control Recruiting nowThis early study tests a new treatment called IASO207 for people with active lupus that hasn't responded to standard therapies. The treatment works by creating special immune cells inside the body to target and calm the overactive immune system. The study will check if it's safe …
Phase: EARLY_PHASE1 • Sponsor: Peking University People's Hospital • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
New drug could tame lupus kidney flares
Disease control Recruiting nowThis study tests whether adding the drug iptacopan to standard treatment helps people with active lupus nephritis (kidney inflammation caused by lupus) achieve better kidney function and fewer flares. About 240 adults with confirmed lupus nephritis will receive either iptacopan o…
Phase: PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
New hope for rare muscle disease: baricitinib trial aims to cut steroid use
Disease control Recruiting nowThis Phase 3 trial tests whether baricitinib, a JAK inhibitor pill, can improve symptoms of dermatomyositis (a rare autoimmune disease causing muscle weakness and skin rashes) while allowing patients to stop steroids. 62 adults with active disease will receive baricitinib or a pl…
Phase: PHASE3 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
New lupus drug enters early human testing
Disease control Recruiting nowThis early-phase trial is testing a new drug called DB-2304 in healthy volunteers and people with lupus (SLE or CLE). The main goal is to check safety and how the body processes the drug. About 148 participants will receive either DB-2304 or a placebo. This is a first step to see…
Phase: PHASE1, PHASE2 • Sponsor: DualityBio Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
New hope for babies with leukemia: immunotherapy combo trial launches
Disease control Recruiting nowThis study tests a new treatment plan for infants (up to 12 months old) with a type of leukemia called acute lymphoblastic leukemia. The goal is to see if adding an immunotherapy drug called blinatumomab can better clear leukemia cells that remain after initial treatment. About 9…
Phase: PHASE1, PHASE2 • Sponsor: Tanja Andrea Gruber • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
New drug hopes to ease rare muscle diseases
Disease control Recruiting nowThis Phase 3 trial tests a drug called dazukibart in people with active dermatomyositis or polymyositis, rare diseases that cause muscle weakness and inflammation. About 318 adults will receive either the drug or a placebo by IV every 4 weeks for 48 weeks. The study aims to see i…
Phase: PHASE3 • Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
Ultrasound and EMG may tell inflammatory from mechanical shoulder issues
Diagnosis Recruiting nowThis study compares muscle thickness around the shoulder blade in people with early ankylosing spondylitis (an inflammatory condition) versus those with mechanical shoulder blade movement problems. Researchers use ultrasound and electromyography (EMG) to see if they can tell the …
Sponsor: Tanta University • Aim: Diagnosis
Last updated Jul 03, 2026 23:00 UTC
-
New genetic test aims to sharpen blood cancer diagnosis
Diagnosis Recruiting nowThis study looks at a new genetic test called Caris Chromoseq for people with certain blood cancers (acute myeloid leukemia, myelodysplastic syndrome, or myeloproliferative neoplasms). The test scans the entire genome to help classify the cancer and guide risk assessment. Researc…
Sponsor: Caris Science, Inc. • Aim: Diagnosis
Last updated Jul 03, 2026 23:00 UTC
-
Glow-in-the-Dark dye could help surgeons spot brain tumors
Diagnosis Recruiting nowThis early-stage trial tests a fluorescent dye called panitumumab-IRDye800 that attaches to cancer cells. Before surgery, 30 adults with brain tumors will receive a single infusion of the dye. During their operation, a special camera will detect the dye's glow, helping surgeons d…
Phase: EARLY_PHASE1 • Sponsor: Eben Rosenthal • Aim: Diagnosis
Last updated Jul 02, 2026 00:00 UTC
-
New PET scan tracer aims to spot blood cancers more clearly
Diagnosis Recruiting nowThis study is testing a new radioactive tracer called 68Ga-EV203 for PET/CT scans in people with blood cancers like multiple myeloma, lymphoma, and leukemia. The goal is to see how the tracer spreads in the body, how much radiation it gives off, and whether it can find tumors bet…
Phase: NA • Sponsor: Zhejiang Cancer Hospital • Aim: Diagnosis
Last updated Jun 28, 2026 00:00 UTC
-
New scan could pinpoint hidden brain tumors in cushing patients
Diagnosis Recruiting nowThis study tests whether a special PET scan (FET PET/CT) can better locate small pituitary tumors that cause Cushing disease. About 50 adults with confirmed Cushing disease who are scheduled for pituitary surgery will receive the scan before their operation. The goal is to see if…
Phase: EARLY_PHASE1 • Sponsor: Mayo Clinic • Aim: Diagnosis
Last updated Jun 27, 2026 14:01 UTC
-
New vaccine aims to shield stem cell patients from dangerous virus
Prevention Recruiting nowThis early-phase trial tests a vaccine (CMV-MVA Triplex) given to both stem cell donors and recipients to boost immunity against cytomegalovirus (CMV) and prevent active infection after a half-matched stem cell transplant. About 46 people with various blood cancers will take part…
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Prevention
Last updated Jul 03, 2026 23:00 UTC
-
Laser eye surgery could prevent blindness in rare genetic condition
Prevention Recruiting nowThis study tests a laser treatment called OSC/SS to prevent retinal detachment in people with Stickler Syndrome, a genetic condition that raises the risk of vision loss. About 500 children and adults will receive the procedure in one or both eyes and be followed for 5 years. Rese…
Phase: NA • Sponsor: Helen Keller Eye Research Foundation • Aim: Prevention
Last updated Jul 03, 2026 00:00 UTC
-
Green tea and vitamin D3 may stop fibroids returning after surgery
Prevention Recruiting nowThis study tests whether taking green tea extract (EGCG) and vitamin D3 daily can prevent uterine fibroids from growing back after surgical removal. About 240 women who have had fibroid surgery will receive either the supplements or a placebo. The goal is to see if this simple co…
Phase: PHASE2 • Sponsor: Sheikh Shakhbout Medical City • Aim: Prevention
Last updated Jun 27, 2026 14:00 UTC
-
Poop pills to prevent transplant rejection? new trial tests fecal transplants in blood cancer patients
Prevention Recruiting nowThis study tests whether a fecal microbiota transplant (FMT) can prevent graft-versus-host disease (GvHD) in 150 adults with blood cancers who receive a stem cell transplant. Patients get a single FMT enema within four weeks of transplant. The main goal is to see if FMT improves …
Phase: PHASE2 • Sponsor: University Hospital, Clermont-Ferrand • Aim: Prevention
Last updated Jun 27, 2026 13:04 UTC
-
New gel injection aims to soothe sore tendons
Symptom relief Recruiting nowThis study is testing a gel called OSTENIL TENDON to see if it safely reduces pain and improves movement in people with tendon problems. Researchers will enroll 84 adults with one of four types of tendinopathy. The main goal is to measure pain changes three months after treatment…
Sponsor: TRB Chemedica AG • Aim: Symptom relief
Last updated Jul 03, 2026 23:00 UTC
-
Diet showdown: three eating plans battle bloating in scleroderma patients
Symptom relief Recruiting nowThis study compares three different diets to see which one best reduces bloating and other stomach symptoms in people with systemic sclerosis (scleroderma). Sixty participants will follow one of three diets for six weeks: a low-FODMAP diet, a diet that removes foods harmful to th…
Phase: NA • Sponsor: University of Michigan • Aim: Symptom relief
Last updated Jul 03, 2026 00:00 UTC
-
Heel pain relief during pregnancy: which Hands-On therapy works best?
Symptom relief Recruiting nowThis study compares two manual therapy techniques—myofascial release and instrument-assisted soft tissue mobilization—for treating plantar fasciitis in pregnant women. Forty-four women in their second or third trimester will receive one of the two treatments over four weeks, alon…
Phase: NA • Sponsor: University of Lahore • Aim: Symptom relief
Last updated Jul 02, 2026 00:00 UTC
-
New study tests which spot on the shoulder nerve best eases chronic pain
Symptom relief Recruiting nowThis study compares two methods of pulsed radiofrequency treatment for the suprascapular nerve in people with chronic shoulder pain from rotator cuff problems. Thirty-two adults aged 40 to 80 will be randomly assigned to receive the treatment at either the suprascapular notch or …
Phase: NA • Sponsor: Ankara City Hospital Bilkent • Aim: Symptom relief
Last updated Jul 02, 2026 00:00 UTC
-
New device aims to stop foggy lenses during brain surgery
Symptom relief Recruiting nowThis trial tests a new anti-fog suction device that keeps the camera lens clear during nose-to-pituitary tumor surgery. Twenty adults with pituitary or craniopharyngioma tumors will either get the device or the usual water-squirt method. The goal is to see if the device reduces f…
Phase: NA • Sponsor: West China Hospital • Aim: Symptom relief
Last updated Jul 02, 2026 00:00 UTC
-
Could a zappy headband ease your Jumper's knee?
Symptom relief Recruiting nowThis study tests whether a gentle brain stimulation technique called tDCS, applied before eccentric knee exercises, can improve pain and function more than exercise alone in people with patellar tendinopathy (jumper's knee). Forty-two adults with chronic knee pain will be randoml…
Phase: NA • Sponsor: University of Valencia • Aim: Symptom relief
Last updated Jun 27, 2026 14:02 UTC
-
Could a Two-Drug shot beat the standard for shoulder pain?
Symptom relief Recruiting nowThis study tests whether adding hyaluronic acid to a standard corticosteroid injection works better for shoulder tendonitis pain than the steroid alone. About 132 adults with confirmed supraspinatus tendinopathy will receive either the combo or a placebo injection. Pain levels ar…
Phase: PHASE3 • Sponsor: Centre Hospitalier Departemental Vendee • Aim: Symptom relief
Last updated Jun 27, 2026 14:01 UTC
-
Glue instead of stitches for mouth biopsies? small trial tests faster healing
Symptom relief Recruiting nowThis study tests whether a special medical glue (tissue adhesive) can replace traditional stitches for closing wounds inside the mouth after a biopsy. Twenty-eight people with small mouth growths will be randomly assigned to get either the glue or stitches. Researchers will measu…
Phase: NA • Sponsor: Damascus University • Aim: Symptom relief
Last updated Jun 27, 2026 14:00 UTC
-
Gentle pilates tested as a pain relief tool for bendy joints
Symptom relief Recruiting nowThis study tests whether Pilates, a gentle mind-body exercise, can help manage pain and other symptoms in people with hypermobile Ehlers-Danlos syndrome or hypermobility spectrum disorder. One hundred adults with persistent pain will be randomly assigned to either Pilates classes…
Phase: NA • Sponsor: Brigham and Women's Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 13:08 UTC
-
Diet showdown: Gluten-Free vs. mediterranean for arthritis relief
Symptom relief Recruiting nowThis study looks at whether changing what you eat can help with rheumatoid arthritis. 66 adults with RA will follow either a gluten-free diet, a Mediterranean diet, or their usual diet for 12 weeks. Researchers will measure disease activity, quality of life, and inflammation to s…
Phase: NA • Sponsor: Hasan Kalyoncu University • Aim: Symptom relief
Last updated Jun 27, 2026 13:07 UTC
-
Can a smarter oxygen device help lung disease patients move more?
Symptom relief Recruiting nowThis study tests whether using a portable oxygen concentrator (a lightweight, battery-powered device) during walking or exercise helps people with interstitial lung disease (ILD) or COPD feel less breathless and be more active in their daily lives. Twenty-four participants will t…
Phase: NA • Sponsor: State University of New York at Buffalo • Aim: Symptom relief
Last updated Jun 27, 2026 13:06 UTC
-
Can a breast cancer drug shrink fibroids? new trial aims to find out
Symptom relief Recruiting nowThis study tests whether the drug letrozole can improve symptoms and shrink fibroids in women with uterine fibroids. 140 participants will receive either letrozole or a placebo daily for 12 weeks. The main goal is to see if letrozole reduces symptom severity and improves quality …
Phase: PHASE4 • Sponsor: University of California, San Francisco • Aim: Symptom relief
Last updated Jun 27, 2026 13:06 UTC
-
Nerve block injection may ease back pain in ankylosing spondylitis patients
Symptom relief Recruiting nowThis study tests whether a single nerve block injection (erector spinae plane block) can reduce persistent back pain in people with ankylosing spondylitis whose disease activity is already controlled by medication. Fifteen adults aged 18–65 will receive the injection and be monit…
Phase: NA • Sponsor: Marmara University • Aim: Symptom relief
Last updated Jun 27, 2026 13:04 UTC
-
New radiation technique may ease cancer bone pain better than standard therapy
Symptom relief Recruiting nowThis phase 3 trial tests whether a precise, high-dose radiation technique (SBRT) provides better pain relief than standard radiation for cancer patients with painful bone metastases not in the spine. About 230 adults with solid tumors and moderate to severe pain will be randomly …
Phase: PHASE3 • Sponsor: Canadian Cancer Trials Group • Aim: Symptom relief
Last updated Jun 27, 2026 13:04 UTC
-
Can facial exercises ease the stiffness of scleroderma?
Symptom relief Recruiting nowThis study tests whether a personalized facial rehabilitation program can help people with systemic sclerosis who have facial tightness and mouth problems. About 60 adults with this rare autoimmune disease will either receive the rehab program or standard care. The goal is to see…
Phase: NA • Sponsor: University Hospital, Strasbourg, France • Aim: Symptom relief
Last updated Jun 27, 2026 13:04 UTC
-
Could a diabetes drug ease stubborn tendon pain?
Symptom relief Recruiting nowThis early study is testing whether metformin, a common diabetes medicine, can reduce pain and help heal chronic Achilles tendon problems. Forty people with long-term tendon pain will take either metformin or a placebo pill for 16 weeks, along with a home exercise program. Resear…
Phase: PHASE1 • Sponsor: James Wang • Aim: Symptom relief
Last updated Jun 27, 2026 13:04 UTC
-
Video workouts vs. doctor visits: which eases heel pain better?
Symptom relief Recruiting nowThis study tests if watching a video of exercises is as good as getting live instruction from a doctor for treating plantar fasciitis, a common cause of heel pain. About 300 adults with heel pain for at least 3 months will be randomly assigned to either a video or an in-person se…
Phase: NA • Sponsor: Balikesir Ataturk City Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 13:03 UTC
-
Spine radiation study aims to cut fracture risk
Symptom relief Recruiting nowThis study tests whether giving spine radiation in one session or two sessions better prevents bone fractures in people with cancer that has spread to the spine. About 130 adults with spine tumors will receive either one or two focused radiation treatments. The goal is to find wh…
Phase: PHASE2 • Sponsor: Case Comprehensive Cancer Center • Aim: Symptom relief
Last updated Jun 27, 2026 13:02 UTC
-
Could a tiny dose of radiation ease myeloma bone pain?
Symptom relief Recruiting nowThis study tests whether a very low dose of radiation (2 Gy) can relieve bone pain in people with multiple myeloma that has spread to the bones. The goal is to see if this gentler approach works as well as standard radiation but with fewer side effects and less disruption to chem…
Phase: NA • Sponsor: University of Southern California • Aim: Symptom relief
Last updated Jun 27, 2026 13:02 UTC
-
New combo therapy aims to knock out bone metastasis pain
Symptom relief Recruiting nowThis study is looking at whether combining two treatments — a minimally invasive procedure called percutaneous ablation and standard radiation therapy — can better relieve pain from bone cancer that has spread. Researchers will follow 120 people whose pain is not controlled by me…
Sponsor: Society of Interventional Oncology • Aim: Symptom relief
Last updated Jun 27, 2026 13:02 UTC
-
Can more radiation zap cancer pain faster?
Symptom relief Recruiting nowThis phase 2 trial tests whether a higher dose of radiation (40-50 Gy over 10 sessions) can better relieve pain from cancer that has spread to bones or other areas. Researchers hope to double the complete pain response rate at one month compared to standard doses. The study invol…
Phase: PHASE2 • Sponsor: Rutgers, The State University of New Jersey • Aim: Symptom relief
Last updated Jun 27, 2026 13:01 UTC
-
2000 volunteers help create a gold standard for cancer blood tests
Knowledge-focused Recruiting nowThis study collects blood and tissue samples from 2000 people—some with cancer and some without—to create a blinded reference set. Researchers will use these samples to evaluate how well new blood tests can detect many types of cancer early. The goal is to improve the accuracy of…
Sponsor: Alliance for Clinical Trials in Oncology • Aim: Knowledge-focused
Last updated Jul 03, 2026 23:00 UTC
-
Lupus secrets revealed: major study tracks disease over time
Knowledge-focused Recruiting nowThis study aims to learn more about how lupus (SLE) develops and changes over time by observing patients and their relatives. Up to 2000 people aged 3 and older with known or suspected lupus, along with their family members, will provide medical history, blood and urine samples, …
Sponsor: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) • Aim: Knowledge-focused
Last updated Jul 03, 2026 23:00 UTC
-
Healthy donors needed to help unlock mysteries of blood cancers
Knowledge-focused Recruiting nowThis study collects blood, bone marrow, skin, saliva, and stool samples from up to 1,000 healthy volunteers aged 18 and older. The samples will be stored in a database for researchers to compare with samples from people who have myelodysplastic syndromes (MDS), a group of blood d…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Jul 03, 2026 23:00 UTC
-
20,000 volunteers needed to decode immune disease genetics
Knowledge-focused Recruiting nowThis study will analyze DNA from up to 20,000 people, including those with immune disorders and their relatives, to find genetic variants linked to conditions like atopy, autoimmunity, and primary immunodeficiency. Researchers will also study how best to return genetic results to…
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Knowledge-focused
Last updated Jul 03, 2026 23:00 UTC
-
Scientists launch deep dive into mysterious inflammatory diseases
Knowledge-focused Recruiting nowThis study aims to understand the causes and progression of systemic juvenile idiopathic arthritis (sJIA) and adult-onset Still's disease (AOSD) by observing up to 2,000 participants over time. Researchers will collect medical history, blood samples, and genetic data to identify …
Sponsor: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) • Aim: Knowledge-focused
Last updated Jul 03, 2026 23:00 UTC
-
Gene hunt in peru: could ancestry hold key to autoimmune diseases?
Knowledge-focused Recruiting nowThis study aims to uncover genetic changes that cause autoimmune diseases in people native to Peru. Researchers will collect blood, urine, and stool samples from 300 participants, including patients with conditions like lupus and rheumatoid arthritis, their family members, and he…
Sponsor: National Human Genome Research Institute (NHGRI) • Aim: Knowledge-focused
Last updated Jul 03, 2026 23:00 UTC
-
Scientists seek genetic clues to mysterious fever diseases
Knowledge-focused Recruiting nowThis study aims to learn more about the genetics and natural history of autoinflammatory diseases, which cause repeated fevers and inflammation. Researchers will study up to 5,000 people, including patients, their relatives, and healthy volunteers. Participants provide blood and …
Sponsor: National Human Genome Research Institute (NHGRI) • Aim: Knowledge-focused
Last updated Jul 03, 2026 23:00 UTC
-
Exercise may turn back the clock for blood cancer survivors
Knowledge-focused Recruiting nowThis study looks at whether a tailored exercise program can help older blood cancer survivors slow down the aging process. Researchers will enroll 180 people aged 50 and older who have had blood cancer. The goal is to see if participants can stick with the exercise plan and if it…
Phase: NA • Sponsor: University of Nebraska • Aim: Knowledge-focused
Last updated Jul 03, 2026 00:00 UTC
-
Massive study aims to unlock secrets of food allergies
Knowledge-focused Recruiting nowThis study looks at the causes and effects of food allergies and related conditions like eczema and eosinophilic esophagitis. Researchers will collect blood, skin, and genetic samples from up to 1,800 people over many years. The goal is to find biomarkers and pathways that explai…
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Knowledge-focused
Last updated Jul 03, 2026 00:00 UTC
-
Blood test may personalize leukemia drug dosing
Knowledge-focused Recruiting nowThis study looks at whether measuring the amount of venetoclax in the blood can help doctors give the right dose to people with newly diagnosed acute myeloid leukemia (AML). Currently, everyone gets the same dose, but drug levels vary a lot between patients. The goal is to find a…
Sponsor: The First Affiliated Hospital of Soochow University • Aim: Knowledge-focused
Last updated Jul 03, 2026 00:00 UTC
-
Massive proton therapy registry aims to unlock secrets of cancer treatment
Knowledge-focused Recruiting nowThis registry collects detailed information from cancer patients treated with proton radiation therapy. Researchers will track treatment plans, side effects, and quality of life over 15 years. The goal is to learn which patients benefit most from this precise form of radiation an…
Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins • Aim: Knowledge-focused
Last updated Jul 02, 2026 00:00 UTC
-
500-Person biobank aims to unlock secrets of autoimmune diseases
Knowledge-focused Recruiting nowThis study is creating a large collection of medical data and blood samples from 450 adults with autoimmune diseases (rheumatoid arthritis, lupus, or scleroderma) and 50 healthy volunteers. Researchers will use advanced lab techniques to find unique biological markers that could …
Sponsor: University Hospital, Montpellier • Aim: Knowledge-focused
Last updated Jul 02, 2026 00:00 UTC
-
Can a simple blood test predict leukemia risk after cancer therapy?
Knowledge-focused Recruiting nowThis study investigates clonal hematopoiesis (CH) — small mutations in blood cells that can arise naturally or after cancer treatment — in adults receiving chemotherapy or radiation for solid tumors like breast, lung, or colorectal cancer. Researchers will collect blood, saliva, …
Sponsor: Dana-Farber Cancer Institute • Aim: Knowledge-focused
Last updated Jul 02, 2026 00:00 UTC
-
Researchers launch major study to unravel mysteries of muscle disease
Knowledge-focused Recruiting nowThis study aims to learn more about myositis, a group of diseases that cause muscle inflammation and damage. Researchers will observe up to 1,200 children and adults with myositis, along with healthy volunteers, to track changes in the immune system and other health problems over…
Sponsor: National Institute of Environmental Health Sciences (NIEHS) • Aim: Knowledge-focused
Last updated Jul 02, 2026 00:00 UTC
-
Scientists track spondyloarthritis in families to uncover clues to severe disease
Knowledge-focused Recruiting nowThis study follows up to 2,000 people with spondyloarthritis (a group of inflammatory joint and spine conditions) and their healthy relatives. Researchers aim to identify symptoms, genetic factors, and medical tests that predict who will develop more severe forms of the disease. …
Sponsor: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) • Aim: Knowledge-focused
Last updated Jul 02, 2026 00:00 UTC
-
Body position may predict fluid needs during keyhole hysterectomy
Knowledge-focused Recruiting nowThis study looks at how a simple monitor called the Pleth Variability Index (PVI) changes during laparoscopic-assisted vaginal hysterectomy. Researchers will track PVI at six key moments when the patient's body position changes, such as tilting the head down or raising the legs. …
Sponsor: Wonkwang University Hospital • Aim: Knowledge-focused
Last updated Jul 01, 2026 00:00 UTC
-
Massive cancer database aims to unlock secrets of the disease
Knowledge-focused Recruiting nowThis study is building a huge registry of information and biological samples from adults with or at risk for many types of cancer, as well as healthy volunteers. Researchers will use this resource to study what causes cancer and how to better prevent, detect, and treat it. The re…
Sponsor: University of Nebraska • Aim: Knowledge-focused
Last updated Jul 01, 2026 00:00 UTC
-
COVID-19's skin secrets: could chilblains hold clues to the virus?
Knowledge-focused Recruiting nowThis study looks at skin problems that appear during a COVID-19 infection, with a special focus on chilblains (painful red or purple bumps on fingers or toes). Researchers want to understand why these skin changes happen—whether from the virus itself, tiny blood clots, or inflamm…
Sponsor: Centre Hospitalier Universitaire de Nice • Aim: Knowledge-focused
Last updated Jul 01, 2026 00:00 UTC
-
New registry aims to unlock secrets of cancer in older adults
Knowledge-focused Recruiting nowThis research study creates a registry of older adults with cancer to collect information about their health, treatments, and outcomes. Participants complete a geriatric assessment and allow researchers to follow their medical records. The goal is to better understand how cancer …
Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Knowledge-focused
Last updated Jul 01, 2026 00:00 UTC
-
Can a natural pill help your ligaments grow stronger?
Knowledge-focused Recruiting nowThis study tests whether a natural supplement can increase collagen production in the body after exercise. Twenty healthy adults will take the supplement or a placebo for a week while doing weight-bearing exercise. Researchers will measure collagen markers in the blood and use th…
Phase: NA • Sponsor: University of California, Davis • Aim: Knowledge-focused
Last updated Jul 01, 2026 00:00 UTC
-
New biomarker study aims to spot lupus kidney disease earlier
Knowledge-focused Recruiting nowThis study follows 500 adults with lupus to see if blood and urine tests can reliably detect kidney inflammation (lupus nephritis). Participants give samples during routine visits, and doctors track their kidney health over time. The goal is to find simple, non-invasive markers t…
Sponsor: Oslo University Hospital • Aim: Knowledge-focused
Last updated Jul 01, 2026 00:00 UTC
-
Lupus drug anifrolumab under pregnancy safety spotlight
Knowledge-focused Recruiting nowThis study is tracking 500 pregnant women with lupus to see if the drug anifrolumab is linked to birth defects or pregnancy loss. Researchers will compare women who took anifrolumab during early pregnancy to those who did not. The goal is to gather real-world safety data, not to …
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Jun 28, 2026 00:00 UTC
-
Study links gum health to rare kidney diseases
Knowledge-focused Recruiting nowThis study looks at gum disease in people with rare kidney disorders like Alport syndrome, Fabry disease, and tuberous sclerosis, as well as lupus. Researchers will compare 100 participants to those with chronic kidney disease and healthy controls. They aim to understand how comm…
Sponsor: Stefan Lujinschi • Aim: Knowledge-focused
Last updated Jun 28, 2026 00:00 UTC
-
New study aims to unlock secrets of systemic sclerosis through patient samples
Knowledge-focused Recruiting nowThis study is gathering blood, stool, and skin samples from 100 adults with systemic sclerosis to learn more about the disease. Researchers will also track health information like skin thickness, lung function, and quality of life over time. The goal is to build a biobank for fut…
Sponsor: University Hospital, Brest • Aim: Knowledge-focused
Last updated Jun 28, 2026 00:00 UTC
-
Scientists launch major study to unravel mysteries of muscle inflammation
Knowledge-focused Recruiting nowThis study aims to collect medical information and tissue samples from 500 people with suspected or confirmed inflammatory muscle diseases, as well as healthy volunteers. Researchers will use blood, muscle, and skin samples to study what causes these diseases and how they progres…
Sponsor: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) • Aim: Knowledge-focused
Last updated Jun 28, 2026 00:00 UTC
-
Lupus drug in breast milk: new study aims to find out
Knowledge-focused Recruiting nowThis study tracks 16 breastfeeding mothers with lupus who are taking anifrolumab. Researchers will measure how much of the drug appears in breast milk and in the mother's and baby's blood. The goal is to understand potential exposure and effects on the breastfed infant.
Phase: PHASE4 • Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Jun 28, 2026 00:00 UTC
-
New study hopes to find a simple test for MS diagnosis
Knowledge-focused Recruiting nowThis study is analyzing inflammatory markers in the blood and spinal fluid of 300 people who are being checked for multiple sclerosis (MS). The goal is to see if certain markers can help doctors tell MS apart from other autoimmune diseases that affect the brain and spinal cord. R…
Sponsor: Centre Hospitalier Universitaire de Nice • Aim: Knowledge-focused
Last updated Jun 28, 2026 00:00 UTC
-
Blood bank aims to predict leukemia risk in MDS patients
Knowledge-focused Recruiting nowThis study gathers blood and bone marrow samples from 150 adults with myelodysplastic syndrome (MDS), a blood disorder that can turn into acute leukemia. Researchers want to find biological markers that help predict which patients are likely to progress to leukemia. The goal is t…
Phase: NA • Sponsor: University Hospital, Brest • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:03 UTC
-
Could a Finger-Prick test replace clinic blood draws for arthritis patients?
Knowledge-focused Recruiting nowThis study is testing a new device called BloodTrackR that lets people with rheumatoid arthritis collect a small blood sample at home using a finger prick and a smartphone app. Twenty participants will try the device and answer questions about how easy it is to use. The goal is t…
Sponsor: University of Ulster • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:03 UTC
-
New screening trial aims to speed up matching of cancer patients to the right treatments
Knowledge-focused Recruiting nowThis study tests a new way to screen patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) by analyzing their bone marrow and blood for specific biomarkers. The goal is to quickly match patients with a treatment trial that targets their cancer's unique mark…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:03 UTC
-
NIH launches major study to uncover why rheumatic diseases hit minorities harder
Knowledge-focused Recruiting nowThis study aims to learn more about the causes of rheumatic diseases—conditions that cause joint pain, stiffness, and swelling—and why they often affect minority groups more severely. Researchers will observe up to 7,500 adults with known or suspected rheumatic disease, providing…
Sponsor: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:03 UTC
-
Lupus patients enrolled in major Long-Term observation study
Knowledge-focused Recruiting nowThis study follows 300 adults with systemic lupus erythematosus (SLE) who are seen by a team of specialists at a hospital in Brest, France. Researchers will collect data on disease patterns, symptoms, and test results over time. The goal is to better understand lupus and improve …
Sponsor: University Hospital, Brest • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:03 UTC
-
Lung cancer drug matching: lab test could personalize treatment
Knowledge-focused Recruiting nowThis study looks at whether testing lung cancer cells in a lab can predict which drugs will work best for each patient. Researchers will collect fluid from around the lungs of 400 people with lung cancer who need drainage for shortness of breath. They will grow the cancer cells i…
Sponsor: Sheba Medical Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:03 UTC
-
Can your genes predict eye damage from a common arthritis drug?
Knowledge-focused Recruiting nowThis study looks at whether certain genes make some people more likely to develop eye damage from the drug Plaquenil, which is used for autoimmune diseases like lupus and rheumatoid arthritis. Researchers will compare people who have had eye damage from Plaquenil with those who h…
Sponsor: National Eye Institute (NEI) • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC
-
Major study aims to uncover hidden heart disease and test steroid treatment
Knowledge-focused Recruiting nowThis study is tracking 1,500 people with cardiac sarcoidosis—a condition where inflammation affects the heart—to learn how doctors currently diagnose and treat it. Researchers will also test whether corticosteroid therapy improves outcomes. The goal is to create better guidelines…
Sponsor: Ottawa Heart Institute Research Corporation • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC
-
Lupus drug anifrolumab under scrutiny in pregnancy safety study
Knowledge-focused Recruiting nowThis study follows 442 pregnant women with moderate-to-severe lupus to see if taking the drug anifrolumab (Saphnelo) during pregnancy affects the health of mothers or their babies. Researchers will compare women who took the drug during pregnancy to those who did not, tracking bi…
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC
-
Blood test may spot hidden sarcoma signals
Knowledge-focused Recruiting nowThis study investigates whether fragments of tumor DNA circulating in the blood can be used to detect and monitor soft tissue sarcoma. Researchers will collect blood and tumor tissue samples from 40 adults with high-risk sarcomas to see if this DNA can serve as a biomarker for ca…
Phase: NA • Sponsor: University Health Network, Toronto • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC
-
New study screens for hidden genetic marker in mysterious mast cell disorders
Knowledge-focused Recruiting nowThis study aims to find how common the KIT D816V mutation is in people with suspected clonal mast cell disease. Researchers will collect blood samples from 450 participants and test them using two sensitive methods. The results may improve understanding and diagnosis of these rar…
Sponsor: Blueprint Medicines Corporation • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC
-
Arthritis drug may mask diabetes, study warns
Knowledge-focused Recruiting nowThis study looks at whether sulfasalazine, a drug for inflammatory arthritis, makes the standard diabetes blood test (HbA1c) falsely low. That could mean diabetes goes undiagnosed or is undertreated in these patients. Researchers will use continuous glucose monitors and fasting b…
Sponsor: Klavs Würgler Hansen • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC
-
Scientists track rare gene variant to unlock blood disorder mysteries
Knowledge-focused Recruiting nowThis study follows people of all ages who have or may have a RUNX1 gene variant, which can cause bleeding problems and increase the risk of blood cancers. Researchers will collect medical history, blood samples, and bone marrow over many years to understand how the condition deve…
Sponsor: National Human Genome Research Institute (NHGRI) • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC
-
Can a website ease the stress of genetic testing? new study aims to find out
Knowledge-focused Recruiting nowThis study is testing a digital platform called the Genetics Navigator to see if it can reduce distress for people undergoing genetic testing. The platform provides education, counseling, and management recommendations. Researchers will compare it to standard care in 170 adults a…
Phase: NA • Sponsor: Unity Health Toronto • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC
-
New study aims to crack Tough-to-Diagnose joint diseases
Knowledge-focused Recruiting nowThis study is collecting joint fluid and tissue samples from 50 adults with inflammatory or non-inflammatory bone and joint diseases. Researchers will use both standard and advanced lab techniques to find new biomarkers that could help diagnose rheumatic diseases more accurately …
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC
-
Scientists hunt for genetic clues behind childhood pituitary tumors
Knowledge-focused Recruiting nowThis study aims to uncover the genetic causes of pituitary and hypothalamic tumors in children. Researchers will collect blood and tumor samples from up to 2,000 participants to analyze DNA and look for inherited patterns. The study also trains doctors and tests new MRI technique…
Sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:01 UTC
-
Massive CML registry launches to reveal how TKIs really perform
Knowledge-focused Recruiting nowThis registry will follow 1,000 adults with chronic-phase CML who are taking approved TKIs (like Gleevec or Tasigna) as their first or second treatment. Over 5 years, researchers will track side effects, treatment changes, and patient-reported experiences to understand how these …
Sponsor: Novartis Pharmaceuticals • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:01 UTC
-
NIH launches study to unlock secrets of rare 'Black Urine' disease
Knowledge-focused Recruiting nowThis study aims to learn more about alkaptonuria, a rare genetic disease that causes a pigment to build up in bones and tissues, leading to arthritis and other problems. Researchers will evaluate 300 patients over several years using advanced medical tests. The goal is to better …
Sponsor: National Human Genome Research Institute (NHGRI) • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:01 UTC
-
Could stress before shoulder surgery predict complications?
Knowledge-focused Recruiting nowThis study looks at whether patients who feel more stressed before shoulder surgery for rotator cuff problems have a harder recovery. Researchers will measure stress levels in 100 adults using a questionnaire before their operation. The goal is to see if high stress is linked to …
Sponsor: Ramsay Générale de Santé • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:01 UTC
-
Lupus drug anifrolumab under safety microscope: does it raise infection or cancer risk?
Knowledge-focused Recruiting nowThis study watches over 3,000 adults with moderate-to-severe lupus to see if the drug anifrolumab increases the risk of serious infections or cancer compared to standard treatments. No new medicine is given—researchers simply analyze health records from people already prescribed …
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:01 UTC
-
New study investigates why some AML patients face early bleeding or clotting risks
Knowledge-focused Recruiting nowThis observational study examines a specific group of patients with a type of acute myeloid leukemia (AML) that has an NPM1 mutation. Researchers want to see if a particular subset, called APL-like, is linked to early blood vessel problems like bleeding or clots. The study will l…
Sponsor: Gruppo Italiano Malattie EMatologiche dell'Adulto • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:01 UTC
-
Scientists launch 20-Year MDS watch to unlock disease secrets
Knowledge-focused Recruiting nowThis study follows people with myelodysplastic syndromes (MDS) for up to 20 years to understand how the disease changes over time. Researchers will collect blood, bone marrow, and other samples from 1,100 participants, including healthy donors. The goal is to learn more about MDS…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Can we predict the best RA drug? new study seeks answers
Knowledge-focused Recruiting nowThis study is looking for clues to predict how well different rheumatoid arthritis (RA) drugs will work in individual patients. Researchers will give 400 adults with RA one or more standard medications and track their response over 16 weeks. The goal is to find genetic or other f…
Phase: PHASE3 • Sponsor: University of Nebraska • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Hunt for hidden cancer genes: families needed to unlock hereditary secrets
Knowledge-focused Recruiting nowThis study aims to discover new genes that may cause certain cancers to run in families. Researchers will collect blood samples and health information from 1,500 people in families where multiple members have had cancer, especially childhood cancers. The goal is to build a regist…
Sponsor: St. Jude Children's Research Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Rare bone disease under the microscope: what causes melorheostosis?
Knowledge-focused Recruiting nowThis study follows adults with melorheostosis, a rare disease that causes bone thickening, pain, and joint problems. Researchers will track how the disease progresses over time, collect genetic samples from patients and their relatives, and look for biomarkers. The goal is to bet…
Sponsor: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
New study tracks how cancer surgery affects Kids' walking
Knowledge-focused Recruiting nowThis study looks at how well children walk after having surgery for bone or soft tissue cancer in their legs. Researchers will use 3D cameras, muscle sensors, and wearable devices to measure movement in 300 children, comparing them to healthy kids of the same age. The goal is to …
Sponsor: St. Jude Children's Research Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Rare sinus cancer study aims to clarify treatment outcomes
Knowledge-focused Recruiting nowThis study follows people with a rare and advanced cancer of the nasal cavity and sinuses called T4 sinonasal adenoid cystic carcinoma. All participants receive the standard treatment: surgery followed by radiation therapy. The goal is to measure how long people live without the …
Sponsor: Eye & ENT Hospital of Fudan University • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Scientists track rare bone cancer to unlock future treatments
Knowledge-focused Recruiting nowThis study follows 300 children and adults with chordoma, a rare bone cancer of the skull base or spine. Researchers will track how the disease progresses over time using imaging, physical exams, and surveys. The goal is to better understand chordoma's behavior to design more eff…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
New screening trial aims to match kids with relapsed leukemia to targeted therapies
Knowledge-focused Recruiting nowThis study screens children and young adults up to age 22 whose leukemia has returned or is hard to treat. By testing their blood and bone marrow, doctors can identify specific genetic markers to match them with the most promising experimental treatments. The goal is to build a r…
Phase: PHASE1, PHASE2 • Sponsor: PedAL BCU, LLC • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Lupus drug may harm ovaries – could a hormone shot help?
Knowledge-focused Recruiting nowThis study surveys women under 40 with lupus who are starting cyclophosphamide, a drug that can damage ovaries and cause infertility. Some received an additional drug called GnRHa to protect their ovaries. Researchers will compare menstrual health and fertility between those who …
Sponsor: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Choice or fixed? study tests how to get better data from young cancer patients
Knowledge-focused Recruiting nowThis study enrolls 400 adolescents and young adults (ages 18-39) recently diagnosed with various cancers. Participants are randomly assigned to either choose which health-related questions they answer or receive a fixed set of questions. The goal is to see if giving patients a ch…
Phase: NA • Sponsor: Eastern Cooperative Oncology Group • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
50,000 childhood cancer survivors join landmark Long-Term health study
Knowledge-focused Recruiting nowThis study follows about 50,000 people who survived childhood cancer (diagnosed before age 21 between 1970 and 1999) and 10,000 of their siblings. Researchers want to understand how cancer treatments like radiation, chemotherapy, and surgery affect health years later. By comparin…
Sponsor: St. Jude Children's Research Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Scientists probe immune cells to unravel a rare leukemia
Knowledge-focused Recruiting nowThis study looks at blood cells from people with chronic myelomonocytic leukemia (CMML) to learn more about how the disease works. Researchers will study specific immune cells, including monocytes and immature granulocytes, to understand why they don't develop normally. The goal …
Sponsor: Centre Hospitalier Universitaire de Nice • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Can lab tests guide better AML treatment choices?
Knowledge-focused Recruiting nowThis study explores whether combining a drug sensitivity test with detailed genetic profiling can help doctors recommend the best treatment for each patient with relapsed or refractory acute myeloid leukemia (AML). Researchers will take extra blood or bone marrow samples from 18 …
Sponsor: City of Hope Medical Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Scientists hunt for clues in blood cancer samples to improve future treatments
Knowledge-focused Recruiting nowThis study is collecting blood, bone marrow, and leftover tissue samples from 550 people with acute myeloid leukemia or follicular lymphoma. Researchers will analyze the samples to find genetic markers that may predict how well treatments work or why some stop working. The goal i…
Sponsor: Tempus AI • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Can your smartphone help fight cancer? new study aims to find out
Knowledge-focused Recruiting nowThis study aims to safely collect health information like heart rate and activity levels from cancer patients using devices like smartphones and wearables. Researchers will use this data to learn more about how it relates to cancer diagnosis, treatment response, and risk factors.…
Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Cured of cushing as a kid? scientists want to track your health for years
Knowledge-focused Recruiting nowThis study looks at the long-term health of people who were cured of Cushing disease before age 21. Researchers want to understand how past high cortisol levels affect the body and mind years later. Participants will complete surveys and have check-ups every 5 years. The goal is …
Sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Leftover surgery tissue could unlock secrets of hardening arteries and bones
Knowledge-focused Recruiting nowThis study uses leftover tissue from heart and orthopedic surgeries to learn more about how calcification (hardening) happens in bones and blood vessels. Researchers will grow cells from these tissues in the lab to study the process. The goal is to better understand the disease, …
Sponsor: Centre Hospitalier Universitaire, Amiens • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Scientists hunt for lung disease genes in 3,500 volunteers
Knowledge-focused Recruiting nowThis study looks at how genes play a role in lung diseases like cystic fibrosis, asthma, and pulmonary fibrosis. Researchers will examine DNA from up to 3,500 people with and without lung disease to find genetic differences. The goal is to better understand what causes these cond…
Sponsor: National Heart, Lung, and Blood Institute (NHLBI) • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Scientists hunt for genes behind rare bone tumor diseases
Knowledge-focused Recruiting nowThis study aims to find the genetic causes of Ollier disease and Maffucci syndrome, rare disorders that cause cartilage tumors and increase cancer risk. Researchers will study 100 people aged 2 and older using blood tests, scans, and genetic sequencing. Participants will stay at …
Sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Heel pain mystery: is the brain making it worse?
Knowledge-focused Recruiting nowThis study looks at whether the brain and nervous system (central sensitization) play a role in the pain of plantar fasciitis, a common cause of heel pain. Researchers will measure pain sensitivity, ultrasound images of the foot, and psychological factors in 128 adults with the c…
Sponsor: Sultan Abdulhamid Han Training and Research Hospital, Istanbul, Turkey • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:08 UTC
-
Can a skin biopsy tell your doctor which treatment will work?
Knowledge-focused Recruiting nowThis study is collecting skin and blood samples from 830 people with chronic inflammatory skin diseases like psoriasis, eczema, and lupus. Researchers want to find biological markers that can predict how well a person will respond to treatment after one year. The goal is to move …
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:08 UTC
-
Could your genes cause pelvic pain? new study seeks answers
Knowledge-focused Recruiting nowThis study aims to find out if chronic pelvic pain conditions like prostatitis and interstitial cystitis can be inherited. Researchers will collect DNA and urine from 500 participants, including family members, to look for genetic links. The goal is to better understand the cause…
Sponsor: Boston Children's Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:07 UTC
-
10,000 joint replacements under the microscope: what makes an implant last?
Knowledge-focused Recruiting nowThis study collects information from 10,000 adults who have had hip or knee replacement surgery at Heidelberg University Hospital. Researchers will follow participants during routine check-ups to see how long the artificial joints last, how well they function, and what problems m…
Sponsor: University Hospital Heidelberg • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:07 UTC
-
Scientists hunt for clues to improve leukemia treatment after transplant
Knowledge-focused Recruiting nowThis study looks at blood cells from 20 adults with acute myeloid leukemia (AML) whose cancer returned after a stem cell transplant. All participants have specific genetic changes (NPM1 mutations or KMT2A rearrangements) and are being treated with a menin inhibitor. Researchers w…
Sponsor: University of Freiburg • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:07 UTC
-
Poop pills for cancer patients? pilot study tests fecal transplants in High-Risk therapies
Knowledge-focused Recruiting nowThis pilot study is testing whether fecal microbiota transplantation (FMT) — giving processed stool from a healthy donor via enema — is safe and doable in 20 patients with lymphoma or leukemia who are receiving CAR-T therapy or stem cell transplants. The goal is to see if at leas…
Phase: NA • Sponsor: University Health Network, Toronto • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:07 UTC
-
Could your environment trigger this rare muscle disease?
Knowledge-focused Recruiting nowThis study investigates whether certain environmental exposures—like infections, stress, or sun exposure—are more common in people with anti-synthetase syndrome, a rare autoimmune condition that causes muscle weakness and lung disease. Researchers will compare 580 participants, i…
Sponsor: National Institute of Environmental Health Sciences (NIEHS) • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:07 UTC
-
Can an arthritis drug also help fatty liver? new study investigates.
Knowledge-focused Recruiting nowThis study looks at 20 adults with psoriatic arthritis and fatty liver disease to see if the drug guselkumab can improve liver fat, joint swelling, and skin plaques. Participants will have two visits over 24 weeks to track changes. The goal is to understand shared disease mechani…
Phase: NA • Sponsor: University of California, San Diego • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:07 UTC
-
Coin flip chemo: study tests if patients will let a computer choose their treatment strength
Knowledge-focused Recruiting nowThis study looks at whether adults with acute myeloid leukemia (AML) who are not healthy enough for strong chemotherapy are willing to let a computer randomly assign them to either lower- or higher-intensity treatment. The goal is to see if this approach is acceptable to patients…
Phase: NA • Sponsor: Fred Hutchinson Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:07 UTC
-
Massive study to track what happens when AML comes back
Knowledge-focused Recruiting nowThis observational study will follow 4,000 people whose acute myeloid leukemia has returned or not responded to treatment. Researchers will collect data from routine care to understand survival rates and treatment patterns over up to 4 years. No new drugs are being tested; the go…
Sponsor: Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:06 UTC
-
Lupus patients who failed multiple drugs under observation in new study
Knowledge-focused Recruiting nowThis study is observing 223 people with active lupus (including kidney inflammation) who haven't gotten better with steroids and at least two immunosuppressants. Researchers want to see how well today's standard treatments work for these tough cases. The goal is to measure how ma…
Sponsor: Bristol-Myers Squibb • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:06 UTC
-
Leukemia drug study probes thinking and memory side effects
Knowledge-focused Recruiting nowThis study looks at whether targeted cancer drugs called TKIs affect brain health and well-being in people with chronic leukemia. Researchers will compare 400 patients who receive TKI therapy to those who do not. The goal is to understand if these treatments cause cognitive chang…
Sponsor: University of Rochester NCORP Research Base • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:06 UTC
-
Massive study tracks lung disease progression in 4,000 patients
Knowledge-focused Recruiting nowThis study follows 4,000 people with interstitial lung disease (including conditions like pulmonary fibrosis and sarcoidosis) to understand how the disease naturally changes over time. Researchers will collect medical data and blood samples, and compare them to a healthy control …
Sponsor: University of Chicago • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:05 UTC
-
Lupus Patients' shingles vaccine response under the microscope
Knowledge-focused Recruiting nowThis study looks at how well the shingles vaccine (Shingrix) works in people with lupus compared to healthy people of the same age and sex. Researchers will measure immune cell responses after two doses and follow participants for up to 5 years. The goal is to understand if the v…
Sponsor: Seoul National University Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:05 UTC
-
Massive gene hunt aims to unlock secrets of blood disorders
Knowledge-focused Recruiting nowThis study collects blood, bone marrow, and other samples along with health information from up to 1,716 people with non-cancerous blood diseases and their family members. Researchers will analyze the participants' genes to find new genetic causes of these conditions and understa…
Sponsor: St. Jude Children's Research Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:04 UTC
-
New study aims to unlock secrets of rare cholesterol diseases
Knowledge-focused Recruiting nowThis natural history study is observing up to 250 people with Smith-Lemli-Opitz syndrome and related cholesterol disorders, as well as their relatives. Researchers will track symptoms, development, and lab results over several years to find better ways to measure disease progress…
Sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:04 UTC
-
Scientists decode immune clues to improve leukemia treatment
Knowledge-focused Recruiting nowThis study collects blood and bone marrow samples from 80 adults newly diagnosed with acute myeloid leukemia (AML). Researchers will measure inflammasome activity before and after standard chemotherapy to see if it relates to how well the treatment works. The goal is to better un…
Sponsor: Ciceri Fabio • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:04 UTC
-
Smartphone addiction may worsen neck problems in arthritis patients
Knowledge-focused Recruiting nowThis study looks at how heavy smartphone use impacts neck posture, muscle strength, balance, and tongue pressure in people with rheumatoid arthritis or ankylosing spondylitis. Researchers will compare these patients to healthy individuals to separate the effects of the disease fr…
Sponsor: Merve Şahin • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:04 UTC
-
New study aims to uncover why RA patients struggle to swallow
Knowledge-focused Recruiting nowThis study looks at why people with rheumatoid arthritis (RA) may have trouble swallowing. Researchers will use a small, flexible camera to examine the throat and voice box in 137 adults with RA. They aim to find factors that predict swallowing difficulty and see if joint problem…
Sponsor: Tanta University • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:04 UTC
-
Smartwatches could predict complications in bone cancer patients
Knowledge-focused Recruiting nowThis study is testing whether a smartwatch can track changes in walking and daily activities in people with bone cancer (osteosarcoma or metastatic bone disease). The goal is to see if the watch can help doctors spot problems early and personalize care. About 60 participants will…
Phase: NA • Sponsor: Case Comprehensive Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:04 UTC
-
Tiny trial tracks leukemia Drug's journey through the body
Knowledge-focused Recruiting nowThis early-stage study with 10 adults with acute leukemia looks at how the body absorbs, breaks down, and gets rid of the drug bleximenib. Participants take a radioactive version of the drug so researchers can track it in urine and stool. The goal is to understand the drug's path…
Phase: PHASE1 • Sponsor: Janssen Research & Development, LLC • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:03 UTC
-
New navigation tech aims to improve hip replacement accuracy
Knowledge-focused Recruiting nowThis study looks at how well a non-invasive navigation system helps surgeons place the hip cup during total hip replacement. About 118 people with hip conditions like arthritis or hip dysplasia will take part. The goal is to see if the actual cup position matches the planned posi…
Phase: NA • Sponsor: DePuy Orthopaedics • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:03 UTC
-
No travel needed: new study uses video calls to uncover genetic secrets of childhood muscle disease
Knowledge-focused Recruiting nowThis study aims to learn why myotonic dystrophy type 1 affects children differently than adults, and why symptoms vary even within the same family. Researchers will observe 100 children (ages 0-17) through video calls and simple at-home activities, and analyze their genes from a …
Sponsor: University of Rochester • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:03 UTC
-
High-Tech insoles aim to ease arthritis foot pain
Knowledge-focused Recruiting nowThis study aims to create better custom insoles for people with rheumatoid arthritis who have foot pain. Researchers will use CT scans and motion analysis to build a digital model of how feet move and apply pressure. The goal is to design insoles that reduce pain and improve comf…
Phase: NA • Sponsor: Centre Hospitalier Universitaire de Saint Etienne • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:02 UTC
-
Gut bacteria linked to cancer survivor symptoms?
Knowledge-focused Recruiting nowThis study follows 600 childhood cancer survivors aged 8-18 to understand why symptoms like fatigue, pain, and depression often occur together. Researchers will use questionnaires and stool samples to see if gut bacteria and their byproducts play a role. The goal is to find bette…
Sponsor: The Children's Hospital of Zhejiang University School of Medicine • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:02 UTC
-
New study checks if cancer drug olutasidenib changes how other medicines work
Knowledge-focused Recruiting nowThis study looks at how the cancer drug olutasidenib affects the way the body processes other medications. Researchers will give 16 adults with IDH1-mutated cancers a mix of test drugs before and during olutasidenib treatment to measure changes in drug levels. The goal is to ensu…
Phase: PHASE4 • Sponsor: Rigel Pharmaceuticals • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:02 UTC
-
5,000 patients to help unlock secrets of inflammatory heart disease
Knowledge-focused Recruiting nowThis study aims to learn how well heart scans (MRI, ultrasound, PET) can detect and predict outcomes in people with suspected or known inflammatory heart diseases. Researchers will follow 5,000 adults for one year to see how often heart involvement is confirmed and how it affects…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:02 UTC
-
Crushed cancer pill study aims to help kids who Can't swallow tablets
Knowledge-focused Recruiting nowThis study looks at how the body processes venetoclax when the tablet is crushed and mixed into a liquid. It includes 30 children and young adults with blood cancers who already take venetoclax this way. The goal is to measure drug levels in the blood and spinal fluid to ensure t…
Sponsor: Children's Hospital Medical Center, Cincinnati • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:02 UTC
-
NIH launches major study to unlock secrets of rare inflammatory diseases
Knowledge-focused Recruiting nowThis study follows up to 5,000 people with autoinflammatory diseases (like NOMID, CANDLE, and juvenile dermatomyositis) and their healthy relatives. Researchers will collect medical history, blood samples, and imaging over 2-5 day visits to learn how these diseases work and find …
Sponsor: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:02 UTC
-
New study aims to map Real-World care for myelofibrosis patients with anemia
Knowledge-focused Recruiting nowThis study is following 200 people in Germany who have myelofibrosis (a type of bone marrow cancer) and anemia (low red blood cells). Researchers will track which treatments patients receive, how their disease responds, and how they feel over time. The goal is to gather real-worl…
Sponsor: iOMEDICO AG • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:02 UTC
-
Robot arm aims to make bone procedures safer and more precise
Knowledge-focused Recruiting nowThis study is testing a robotic system called Epione to help doctors place needles or instruments into the bones of the pelvis and spine. The goal is to see if the robot makes these procedures more feasible, safe, and accurate compared to doing them by hand. Sixty adults who are …
Phase: NA • Sponsor: Precision IO Group • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:02 UTC
-
New study aims to simplify diagnosis of autoimmune platelet disorder
Knowledge-focused Recruiting nowThis study is testing whether a specialized blood test (MAIPA) can accurately identify autoimmune thrombocytopenia (ITP) in patients with low platelet counts. Currently, ITP is diagnosed by ruling out other causes, which can be slow and uncertain. Researchers will collect blood s…
Phase: NA • Sponsor: University Hospital, Bordeaux • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:01 UTC
-
Can immune cell clues predict transplant success in leukemia?
Knowledge-focused Recruiting nowThis study tracks T-cell changes in 250 acute myeloid leukemia patients receiving a stem cell transplant. By analyzing blood samples with advanced gene sequencing, researchers hope to understand if the immune system plays a key role in recovery and complications. The goal is to f…
Sponsor: University of Southern California • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:01 UTC